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Globally, colorectal cancer (CRC) is the third most common cancer with an incidence 
of approximately 1.3 million cases annually. In 2014, screening for CRC was imple-
mented in Denmark, and during the same year, 5,186 people were diagnosed with 
CRC. The survival of CRC patients is closely related to the stage at the time of diag-
nosis prompting the importance of early detection. CRC takes several years to de-
velop, and have known precursor lesions (adenomas). Like most solid cancers, CRC 
develops through several molecular alterations. Known driver mutations include APC 
and KRAS mutation, which provide growth advantages for neoplastic cells fuelling 
the adenoma to carcinoma sequence.  
DNA hypermethylation is a normal molecular phenomenon in eukaryotic cells. Un-
der normal conditions, this phenomenon is under strict regulation, and primarily in-
volved in regulating embryological development. In different disease states, how-
ever, hypermethylation of the DNA promoter region infers a transcriptional down-
regulation, and hypermethylation of tumour suppressor genes is a frequent event in 
the early stages of CRC development. DNA fragments are constantly present in the 
circulation, termed cell-free DNA. The cell-free DNA can be analysed for aberrant 
methylation which could be used as biomarkers for CRC detection, prognostication, 
and disease progression. The aim of this thesis was to ascertain already proven CRC 
hypermethylation biomarkers with regards to their capabilities for CRC detection and 
prognostication.  
In order to select biomarkers for further analysis we conducted a systematic literature 
review. Previous studies have identified approximately 70 different hypermethylated  
genes promoter regions as blood or stool based biomarkers for CRC. Some of these 
individual biomarkers seems to be able to distinguish early stage CRC patients from 
healthy controls (e.g. APC, NEUROG1, RASSF1A, RASSF2A, SDC2, SEPT9, and 
THBD). SEPT9 is already commercialised as a blood based biomarker for CRC de-
tection. However, a large-scale cross-sectional study in 1.457 screening subjects re-
vealed a sensitivity of only 48.2%. Combined hypermethylation biomarker assays 
have revealed sensitivities and specificities above 90% (APC, MGMT, RASSF2A, and 
WIF1) suggesting that the combination of multiple hypermethylation biomarkers 
could increase clinical utility.  
We evaluated 30 of the DNA promoter regions found in the aforementioned literature 
study. Through the analysis of plasma samples from 193 CRC patients and 102 co-
lonoscopy verified healthy controls, we found that each individual cell-free hyper-
methylated biomarker only provided a sensitivity of 30% at a reasonable specificity. 
Seven hypermethylated promoter regions (ALX4, BMP3, NPTX2, RARB, SDC2, 




72.5% specificity. The panel had a similar performance when analysing only stage I 
and II CRC patients, indicating that these seven biomarkers could be used for CRC 
screening. Whether this result is reproducible is pending a subsequent validation 
study.  
Moreover, we found, that the majority of the hypermethylated promoter regions in-
ferred a decreased survival compared with patients not having these biomarkers. The 
five-year survival was 79.7% (63.8; 82.3) in patients with a low number of circulating 
hypermethylated promoter regions (< 5) compared with 40.6% (23.8; 56.8) in pa-
tients with a high number (> 10). Two of the DNA biomarkers (RARB and RASSF1A) 
were significant predictors of poor overall survival regardless of CRC stage at the 
time of diagnosis (hazard ratios of 1.99 [1.07; 3.72] and 3.35 [1.76; 6.38] respec-
tively) suggesting aggressive disease. A high number of hypermethylated promoter 
regions was also associated with an increased risk of CRC recurrence (both metastatic 
and regional) with a stage-adjusted three-year risk ratio of 1.91 (0.91; 4.04). This 
difference was, however, not statistically significant. 
In conclusion, individual cell-free hypermethylated DNA promoter regions have a 
limited ability to detect CRC but a panel of seven hypermethylated promoter regions 
show promise as a blood-based biomarker for CRC detection. Moreover, the number 
of circulating hypermethylated promoter regions was associated with a decreased 
overall survival, and a trend towards an increased risk of disease recurrence. These 
findings are in line with previous findings and demand further validation to ensure 





Kræft i tyk- og endetarmen (KRC) er en af hyppigste og mest dødelige kræftformer 
med op imod 1.3 millioner tilfælde årligt på verdensplan. I Danmark er der derfor 
indført screening for KRC, og i 2014 fik 5,186 danskere konstateret sygdommen. 
Overlevelsen er tæt korreleret med stadiet på diagnosetidspunktet, hvilket nødven-
diggør tidlig og sikker diagnostik. KRC udvikler sig over en flerårig periode og har 
kendte forstadier (adenomer og polypper). Ved transformationen fra normal celle til 
kræftcelle opstår der en række molekylære ændringer i cellernes arvemateriale 
(DNA). Mutationer i generne APC og KRAS ses ofte i KRC og giver kræftcellerne en 
vækstfordel i forhold til de omkringliggende normale celler. Disse mutationer er driv-
kræfterne for omdannelse af adenomer til karcinomer (KRC). 
DNA hypermethylering er en normal reguleringsmekanisme i eukaryote celler. Det 
ses som en normal del af den humane embryologiske udvikling, og det medvirker til 
korrekt regulering af, hvilke gener der udtrykkes. Hypermethylering af startsekven-
sen af forskellige gener fører til inaktivering. I den tidlige udvikling af forskellige 
kræftformer ses det, at gener, som er involveret i celledeling og differentiering, bliver 
hypermethylerede og dermed gjort inaktive. Når disse gener bliver inaktive, vil cellen 
ikke længere være underlagt de sædvanlige kontrolmekanismer, og kan derfor poten-
tielt udvikle sig til en kræftcelle. Det er muligt at isolere humant DNA fra blodprøver. 
Dette DNA kan derpå analyseres for hypermethylering, hvilket potentielt kan bruges 
som markør for KRC. Projekts formål var, at undersøge om DNA hypermethylering 
målt i blodprøver kunne bruges til diagnosticere tyk- og endetarmskræft. Herudover 
var det hensigten, at undersøge om disse blodbårne markører kunne anvendes til at 
differentiere mellem KRC patienter med en god prognose og patienter med en dårlig 
prognose. 
De individuelle KRC specifikke hypermethyleringsmarkører blev udvalgt på bag-
grund af et litteraturstudie. Tidligere studier har identificeret ca. 70 forskellige hy-
permethylerede gener som potentielle KRC markører i blod- og afføringsprøver. 
Nogle af disse individuelle markører er fundet i blodet i tidlige stadier af KRC (f.eks. 
APC, NEUROG1, RASSF1A, RASSF2A, SDC2, SEPT9, and THBD), og SEPT9 an-
vendes allerede i en kommerciel test. Hvorvidt SEPT9 er en klinisk anvendelig mar-
kør er dog til debat. Et stort tværsnitsstudie (1.457 screeningspatienter) viste at 
SEPT9 kun havde en sensitivitet på 48.2%. Andre studier, som har kombineret flere 
markører (APC, MGMT, RASSF2A, og WIF1), har vist mere lovende resultater med 
sensitivitets og specificitetsestimater over 90%. Dette tyder på, at en kombination af 
flere hypermethyleringsmarkører bør anvendes, for at højne sensitiviteten. 
Fra vores litteraturstudie udvalgte vi 30 markører til videre analyse. Disse markører 




Ud fra disse blodprøver fandt vi, at hver enkelt markør kun havde en sensitivitet på 
ca. 30%. Dog kunne syv af de analyserede markører (ALX4, BMP3, NPTX2, RARB, 
SDC2, SEPT9, and VIM) adskille de to grupper med 90.7% sensitivitet og 72.5% 
specificitet. Markørerne kunne identificere KRC patienter i tidligt stadie (stadie I og 
II) med lignende performance, hvilket indikerer at markørerne kan bruges til scree-
ningen for KRC. Om dette markørpanel kan anvendes i det danske screeningspro-
gram afventer et opfølgningsstudie. 
Ydermere fandt vi, at langt hovedparten af de undersøgte hypermethyleringsmarkører 
var udtryk for en dårlig prognose. Femårsoverlevelsen hos KRC patienter med under 
fem markører i blodet var 79.2% (63.8; 82.3) sammenlignet med 40.6% (23.8; 56.8) 
hos patienter med mere end ti markører. Specielt var tilstedeværelsen af RARB og 
RASSF1A hypermethylering et dårligt prognostisk tegn (stadiejusterede hazard rater 
på hhv. 1.99, 95%CI [1.07; 3.72] og 3.35, 95%CI [1.76; 6.38]). Et højt antal hyper-
methyleringer var endvidere et udtryk for øget for recidivrisiko med en stadiejusteret 
tre års risiko ratio på 1.91 (0.91; 4.04), hvilket dog ikke var statistisk signifikant. 
Som konklusion kan individuelle hypermethyleringsmarkører ikke anvendes som 
blodbårne markører for KRC. Det ser dog ud til, at et panel af syv markører kan 
anvendes som screeningstest for KRC. Ydermere er et højt antal af disse markører et 
udtryk for dårlig prognose og en øget risiko for recidiv. Disse fund er sammenligne-
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CHAPTER 1. INTRODUCTION 
1.1. COLORECTAL CANCER 
Colorectal cancer (CRC) arises from the cell lining of the large intestine. The current 
thesis focuses on the epigenetic alterations in CRC, and the following sections will 
provide the reader with an overview of the different aspects of the disease. 
 
1.1.1. ANATOMY OF THE LARGE INTESTINE 
The human gastrointestinal tract (GI) is a hollow organ, arising in the oral cavity and 
ending in the anal canal. The primary function is to ensure transportation, digestion, 
and absorption of ingested nutrients. Moreover, it has a wide range of secondary 
functions encompassing the immune, endocrine, and cardiovascular system.  
The GI tract is divided into several sections, due to embryological origin, anatomical 
location, physical appearance, and physiological function. The large intestine is the 
last part of the GI tract. It extends from the terminal part of the small intestine (the 
ileum) to the anus. It is approximately 1.5 m in length, and it is relatively more fixated 
than the small bowel.  
 
Figure 1 Schematic drawing of the colon and rectum, with blood-supply 
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The primitive intestinal tube develops from the endodermal roof of the yolk sac, be-
ginning as a simple tubular shaped organ suspended by one common mesentery. The 
embryological development is completed through a complex set of rotations, after 
which it settles at the posterior abdominal wall.1,2 Each part of the large intestine 
receives its blood supply according to its embryological development (midgut vs. 
hindgut), with the lymphatic drainage following the arterial blood supply (Figure1). 
The intestinal wall is composed of four layers: (i) mucosa, (ii) submucosa, (iii) mus-
cularis, and (iv) serosa. The innermost layer (the mucosa) consists of a single layer 
of cells (the colonic epithelium) which undergoes continuous renewal.1 The glandular 
epithelium forms cylindrical crypts. The bottom of the crypts consists of proliferative 
and undifferentiated cells, which undergo differentiation into mature colonic epithe-
lial cells at the top of the crypts. The fundamental pathway of colonic differentiation 
involves several complex intercellular signalling systems.3 A detailed description of 
these systems is beyond the scope of this thesis. However, a large proportion of the 
genetic and epigenetic alterations in CRC affect embryological signalling pathways 
(e.g. APC, BMP3), displaying the interplay between embryological colonic develop-
ment and CRC.  
 
1.1.2. FUNCTION OF THE LARGE INTESTINE 
Whereas almost all digestion and absorption of dietary nutrients occurs in the small 
intestine, the main function of the large intestine is the reabsorption of water and 
electrolytes. In this regard, the colon also absorbs some of the vitamins produced by 
intestinal bacteria (importantly menaquinones). It also stores the compacted faecal 
matter before evacuation during defaecation.   
The large intestine also houses the largest amount of intestinal bacteria with more 
than 700 different species represented. The different microbes number more than 100 
trillion weighing approximately 200 grams. The bacterial diversity differs to that of 
other parts of the intestine.4 Most of these bacteria are commensals, meaning that 
they do not infer disease. However, in relation to other disease entities, or to antibiotic 
treatment, these bacteria may become virulent (e.g. clostridium difficile). Moreover, 
changes in the intestinal microbiome, have been linked to different disease entities 
(e.g. ulcerative colitis, Crohn’s disease).5–7 It is also believed, that these microbes and 
their metabolic output play an intricate part in CRC development, perhaps by influ-





1.1.3. EPIDEMIOLOGY AND RISK FACTORS 
Globally, CRC is the third most common cause of cancer (1.3 million/year) and the 
fourth leading cause of cancer related deaths (700,000/year).9 Denmark, like most 
other western European countries, has a high incidence - roughly 70-90 cases per 
100,000 persons per year.10 The incidence in Denmark has risen in recent years, in 
part due to the introduction of the CRC screening programme in 2014 (described in 
detail below). In other high-income countries like the USA, the incidence has stabi-
lised or started to decrease. This could be due to various screening programmes or 
colonoscopy with the removal of premalignant lesions, however, the decrease could 
also be attributed to changes in lifestyle and other unknown factors .11 
CRC is a multi-factorial disease without one sole factor accounting for the majority 
of cases. Age is the most predominant risk factor, with more than 90% of CRC cases 
being diagnosed in patients above 50 years of age. In Denmark, the median age for 
CRC diagnosis is 72 years for colon cancer and 70 years for rectal cancer (Figure 2).  
 
Figure 2 The annual incidence of colorectal cancer in Denmark (2014)  
The number of colorectal cancer cases according to age in years 
The established preventive factors include physical activity, acetylsalicylic acid, hor-
mone replacement therapy, and colonoscopy with the removal of precancerous le-
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= 0.73, 95%CI [0.66-0.81]) and a 26% lower risk of distal CRC (RR = 0.74, 95%CI 
[0.68, 0.80]), indicating no association by CRC subsite.12 Ever usage of either oes-
trogen therapy (RR = 0.79, 95%CI [0.69, 0.91]) or oestrogen-progesterone therapy 
(RR = 0.74, 95%CI [0.68, 0.81]) has been associated with a decreased CRC risk, 
however the former use of oestrogen therapy infers no risk reduction (RR = 0.86, 
95%CI [0.67, 1.11]).13 Colonoscopy has been associated with a 77% lower risk of 
CRC (OR = 0.23, 95%CI [0.19-0.27]), with the largest reduction in risk being for left 
sided tumours (OR = 0.16, 95%CI [0.35, 0.20]) compared to right sided tumours (OR 
= 0.44, 95%CI [0.35, 0.55]).14 Flexible sigmoidoscopy on its own also infers a benefit 
with a reduced risk of left sided tumours (RR = 0.67, 95%CI [0.59, 0.76]) and a de-
crease in CRC related mortality (RR = 0.72, 95%CI [0.65, 0.76]).15 The effect of 
once-only sigmoidoscopy is emphasised in a incidence reduction of all CRC by 23% 
(HR = 0.77, 95%CI [0.70, 0.84]) and a reduction in CRC related mortality by 31% 
(0.69, 95%CI [0.45, 0.72]).16  
Table 1 Risk and preventive factors for colorectal cancer 





Medical factors  
Family history 
Inflammatory bowel disease 
Diabetes 
Helicobacter pylori infection 
Other infections 
Colonoscopy 












Lifestyle factors  
Smoking 







Dietary factors  
High consumption of red and processed meat 
Fruit and vegetables 








Note: ↑↑↑ = very strong risk increase. ↑↑ = strong risk increase. ↑ = moderate risk increase. 
↓↓ = strong risk reduction. ↓ = moderate risk reduction. Parentheses indicate probable but 
not established associations. Adapted from Brenner et al. (2014).17 
Other lifestyle factors associated with decreased risk of CRC and CRC related deaths 
include: low alcohol consumption, low dietary intake of red or processed meat, low 




Approximately 15-35% of CRC patients have a family history of colorectal neo-
plasms, with known causative germline alterations being present in ~5%.24 Genome 
wide association studies (GWAS), have identified a number of common single-nu-
cleotide polymorphisms (SNPs) associated with increased CRC risk, however, the 
known SNPs only account for less than 7.42% of CRC heritability.25 The search for 
other genetic risk factors accounting for the large heritability in CRC is therefore 
ongoing. The inherited syndromes of CRC with causative genetic alterations can 
broadly be classified into three groups based on clinical presentations: (i) Adenoma-
tous polyposis syndromes, (ii) Nonpolyposis syndromes, and (iii) Hamartomatous 
polyp syndromes, each with distinct genetic alterations.26 The inherited syndromes 
are more frequent in the younger population, and have varying disease penetrance. 
Hereditary nonpolyposis colorectal cancer (HNPCC) infers a lifetime risk of approx-
imately 50-60% compared with ~100% in Familial adenomatous polyposis (FAP).24 




The prognosis of CRC relates to the underlying cancer biology and in patient comor-
bidity. However, stage at the time of diagnosis remains the most important prognostic 
factor. The relative five-year survival for patients diagnosed with CRC in the U.S. 
from 2001 to 2007 was 90.1% in patients with localised disease, 69.2% in patients 
with locoregional spread, and 11.7% in patients with disease dissemination.27 In Den-
mark, the survival is very similar, albeit somewhat lower, with an absolute five-year 
survival of 84.0% in early stage CRC patients and 13.0% in patients with distant 
metastases.28  
The incidence of CRC and the CRC related mortality has dropped in recent years 
(Figure 3). This decrease can be attributed to four main categories. First, current treat-
ments have improved compared to twenty years ago. Second, patients are increas-
ingly aware of the early signs of CRC. At the same time, widespread availability and 
use of endoscopy has lowered the threshold for examination, with earlier diagnosis 
and polypectomy leading to both a decrease in incidence and mortality. Third, there 
could be fewer cases of CRC occurring in the first place, perhaps due to a reduction 
in the numerous risk factors listed above (Table 1). Finally, a large proportion of the 
reduced risk and mortality should be attributed to CRC screening programmes.  
While the mortality and incidence have seen a steady decrease in the U.S. and other 
western countries, CRC incidence rates have increased in Denmark along with other 
countries.29 CRC therefore remains a large disease burden, both on an individual 
level, but also with regard to the direct costs of medical care and lost productivity.30  
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Figure 3 Number of unadjusted annual new cases and deaths of CRC in the U.S.  




Given that CRC develops over a relatively long time-period (~10 years), the high 
incidence rate, lack of early stage symptoms, increased risk by age, and potential cure 
with early stage detection, makes CRC ideal for population based screening.  Cur-
rently, there are two main strategies for CRC screening: (i) sigmoidoscopy, and (ii) 
faecal occult blood testing. A Cochrane meta-analysis concluded, that both methods 
reduce the CRC specific mortality without a reduction in all-cause mortality, promot-
ing the usage of both methods.32 The advantage of stool-based screening is that it is 
cheap and non-invasive. While endoscopy-based screening is an invasive procedure, 
it offers the potential for intervention with the removal of pre-malignant lesions. In 
Denmark, a positive stool test is followed by colonoscopy. 
In Denmark, CRC screening was introduced in 2014. The introduction of the screen-
ing programme was based on the studies above, and a feasibility study, which sug-
gested improved survival in CRC patients diagnosed in the screening population 




























The national screening programme relies on the immunochemical faecal occult blood 
test (iFOBT), which has been preferred over the guiac-based test, due to increased 
sensitivity and specificity, improved patient compliance, and the lack of dietary re-
strictions.34,35 The introduction of the Danish screening programme led to an instant 
increase in CRC cases by ~20% compared to the years preceding screening.10,36 This 
is in sharp contrast to the decreasing incidence rates from the U.S. (Figure 3).  
The adherence to CRC screening programmes are, however, not optimal. According 
to the National Health Interview Survey of 1987, only 23% of the U.S. population 
had recently been screened. In 2005 this proportion was only increased to 50%, dis-
playing the need for improved screening methods.37 This problem is further under-
lined by a Canadian study, suggesting that CRC screening adherence rates may be as 
low as 25% for stool based screening methods.38 According to the annual report from 
the Danish Colorectal Cancer Screening Database adherence for CRC screening was 
63% (95%CI [63, 64]) through the first 22 months after the initiation of the screening 
programme.39 While the Danish compliance is superior to the adherence rates 
achieved in North America, the goal is still to increase compliance to at least 65%. 
In the U.S., the goal is even more ambitious. The goal is to reach an 80% adherence 
rate by 2018, especially by increasing access and awareness. This could possibly lead 
to a decrease in new cancer cases by ~280.000 and averting ~200.000 cancer deaths 
by 2030, showing the massive impact of compliance on screening programmes.40  
The implementation of other less invasive methods could also increase CRC screen-
ing compliance.  
 
1.1.6. PATHOLOGY 
Neoplasms are an abnormal growth of tissue, usually not containing cysts or liquid 
areas. These tumours may be benign or malignant, depending on origin, the presence 
of cellular dysplasia, and growth patterns. In general, tumours derived from the epi-
thelial cell-lining of the large intestine can be divided into two groups; adenomas and 
colorectal adeno-carcinomas. Other tumours of the large intestine account for less 
than 5%. The focus for the current thesis is the colorectal adenocarcinoma.  
The pathological description of colorectal neoplasms relies on the morphology of the 
colonic epithelial cells. Immunohistochemistry is utilised in order to investigate some 
of the underlying molecular abnormalities in especially CRC. The structural abnor-
malities in colorectal neoplasia, will be described in the following, and the underlying 
molecular mechanisms is described in the section on molecular characteristics. 
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ADENOMA 
The colorectal adenoma is the most frequent form of colorectal neoplasia in the west-
ern world. The frequency of adenomas and the incidence of CRC is directly propor-
tional. In countries with a low risk of CRC, the incidence of colorectal adenomas is 
also low. Factors predisposing adenomas are the same, as the ones listed for CRC.  
The development of adenomas involves dysregulation of proliferation patterns in the 
normal mucosa. The result is increased mitotic activity accompanied by decreased 
apoptotic capacity, resulting in an increased cell-number. The minimal lesion is the 
single crypt adenoma, which originates in so-called aberrant crypt foci.41 These le-
sions are highly unstable and may develop into adenomas. Conventional adenomas 
are classified as tubular, tubulovillous, and villous, based on their structural architec-
ture (Figure 4).42 
Figure 4 Classification of colorectal adenomas 
A) Hyperplastic polyp. B) Low grade tubular adenoma (simple crypt-like dysplastic glands with < 25% villous compo-
nent). C) High grade tubular adenoma (simple crypt-like dysplastic glands with < 25% villous component). D)  Tubu-
lovillous adenoma (intermediate lesions with 25-75% villous component). E) Villous adenoma (simple crypt-like dys-
plastic glands with > 75% villous component). F) Serrate adenoma (adenoma showing sawtooth or stellate (serrate) ar-
chitecture). Christian Thomsen has kindly provided the images. 
Every adenoma (with the exception of the hyperplastic polyp) has the potential for 
malignant transformation with an annual conversion rate of 0.25%.43 An average ad-
enoma patient is therefore only at moderate risk of CRC. Increase in size is closely 
related to increased cellular dysplasia making adenoma size an important risk factor 
for malignant transformation. The rate of conversion is highest in patients with ade-
nomas of villous structure and/or severe dysplasia, with annual conversion rates of 




More than 90% of CRCs are adenocarcinomas originating from the epithelial cells of 
the colorectal mucosa. Other types of CRC are metastases, neuroendocrine tumours, 
melanomas, with squamous cell, adeno-squamous cell, spindle cell, and undifferen-
tiated carcinomas.44 The sporadic adenocarcinoma is the focus of this thesis, and the 
other types will not be described further. Macroscopically, the CRC tumour can take 
one of four forms, with Type 4 being the least aggressive (Figure 5).  
Figure 5 The common macroscopic variants of colorectal adenocarcinoma 
Conventional adenocarcinomas are characterised by glandular formation and grade 
accordingly; well differentiated (>95% glandular formation), moderately differenti-
ated (50-95% glandular formation), and poorly differentiated (<50% glandular for-
mation).44 Furthermore, they are also classified according to cellular morphology: (i) 
Mucinous adenocarcinomas; characterised by >50% extracellular mucin, (i) signet 
ring cell adenocarcinomas; characterised by >50% tumour cells with signet cell fea-
tures (these are by definition poorly differentiated), and (iii) medullary adenocarci-
nomas; characterised by sheets of neoplastic cells with large nuclei and abundant 
cytoplasm (often poorly differentiated). Lastly, immunohistochemical staining is 
conducted for CK20, CK7, CDX2, and mismatch repair deficiency.  
Most colorectal adenocarcinomas are moderately differentiated (70%) (Figure 6). 
Well and poorly differentiated adenocarcinomas account for approximately 10% and 
20% respectively. Low grade tumours include the moderately and well differentiated 
adenocarcinomas. The determination of tumour grade is inherently a subjective ex-
ercise, making the reproducibility low, even among experienced pathologists. 
The pathological report includes the histology of the resected adenocarcinoma, with 
a gross description, histologic type, tumour grade, tumour growth, lymph node in-
volvement, blood vessel invasion, lymphatic invasion, perineural invasion, resection 
margins following surgery, and so forth.44 
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Figure 6 Classification of colorectal adenocarcinomas 
A) Moderately differentiated adenocarcinoma with a lymph node metastasis. B) Mucinous adenocarcinoma with selec-
tive loss of MSH2 and decreased expression of MSH6. C) Signet ring cell adenocarcinoma with decreased expression of 
MLH1 and PMS2. Christian Thomsen has kindly provided the images. 
1.1.7. DIAGNOSIS AND STAGING 
The gold standard for CRC diagnosis remains complete colonoscopy with biopsy-
verification.45 In Denmark, patients are either referred for colonoscopy due to a pos-
itive screening test, or due to symptoms suggestive of lower GI malignancy. The main 




abdominal pain (often colicky in nature) and abdominal distension. Alternating diar-
rhoea and constipation may be associated symptoms. Ulcerative tumours and tumours 
in the left colon may present with visible lower GI bleeding. Moreover, patients may 
have anaemia-associated symptoms in the case of visible of occult GI haemorrhage 
(e.g. pallor, shortness of breath, and fatigue). A somewhat large proportion debut 
with symptoms of metastatic disease (e.g. jaundice, ascites, and hepatomegaly). 
Weight loss is also a common unspecific symptom.  
After CRC is diagnosed, subsequent clinical examination, laboratory tests, and im-
aging are used to detect or exclude metastatic disease. The current imaging modalities 
includes computed tomography (CT), positron emission tomography / computed to-
mography (PET/CT), and magnetic resonance imaging (MRI). CT of the thorax and 
abdomen is used as the primary tool for estimating the extent of tumour formation 
and importantly the detection of possible synchronous lesions, and/or metastases. 
However, MRI and CT are equally accurate, and MRI may be more beneficial in 
determining the involvement of the peritoneal surface or the involvement of regional 
organs - which is utilised in rectal cancer. PET/CT may be used in patients, where 
distant metastases are strongly suspected and not found by conventional CT imaging, 
but it is not recommended in the initial staging protocol.  
The current staging system relies on the assessment of the anatomic extent of the 
disease at the time of diagnosis (Table 2). CRCs are staged according to the tumour-
node-metastasis system (TNM).46,47 The TNM classification is based on the clinical 
and radiological findings of tumour size and degree of direct invasion (T), involve-
ment of locregional lymph nodes (N), and the presence of distant metastases (M). 
Refinement of the staging system, has led to the implementation of several, more 
complex tools. First, it includes a full stratification of the intestinal wall involvement 
and the peritoneal serosa, considering the number of regional lymph nodes involved. 
Second, it is a multidisciplinary tool, incorporating both clinical (pre-treatment clas-
sification: cTNM) and pathologic (postsurgical classification: pTNM, and after pre-
operative chemoradiotherapy: ypTNM) staging approaches. One unique feature of 
the CRC staging system is the in-situ cancer (Tis) which includes stromal invasion 
of malignant cells through the lamina propria and into, but not through, the muscu-
laris mucosa. This is justified because the colorectal mucosa (unlike the mucosa else-
where in the GI tract and other organs) lacks stromal lymphatics, making lymphatic 
metastasis impossible.  
Tumour grade (or the grade of differentiation) has previously been recognised as a 
distinct prognostic factor. However, it has not been incorporated in the current CRC 
staging systems because of the lack of consensus regarding stratification, and the sig-
nificant degree of interobserver variability.48 Consequently, tumour grade was re-
cently removed from the risk factors associated with stage II tumours (Figure 7).   
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Table 2 Colon and rectum cancer staging 
Primary Tumour (T)  
Tis Carcinoma in situ: Intraepithelial or invasion of the lamina propria 
T1 Tumour invades the submucosa 
T2 Tumour invades the muscularis propria 
T3 Tumour invades through the muscularis propria into the pericolorectal tissues 
T4a Tumour penetrates to the surface of the visceral peritoneum 
T4b Tumour directly invades or is adherent to other organs or structures 
Regional Lymph Nodes (N) 
N0 No regional lymph node metastasis 
N1a Metastasis in one regional lymph node 
N1b Metastasis in 2-3 regional lymph nodes 
N1c Tumour deposit(s) in the subserosa, mesentery, or non-peritonealised pericolic or perirectal tissues 
N2a Metastasis in 4-6 regional lymph nodes  
N2b Metastasis in 7 or more regional lymph nodes 
Distant Metastasis (M) 
M0 No distant metastasis 
M1a Metastasis confined to one organ or site (e.g. liver, lung, ovary, non-regional lymph node) 
M1b Metastases in more the one organ/site or the peritoneum 
Anatomic Stage 
 T N M 5-year survival rate 
Stage 0 Tis N0 M0 - 
Stage I T1-2 N0 M0 86.3% 
Stage IIA T3 N0 M0 79.7% 
Stage IIB T4a N0 M0 71.3% 
Stage IIC T4b N0 M0 73.8% 
Stage IIIA T1-T2 N1/N1c M0 85.4% 
 T1 N2a M0  
Stage IIIB T3-T4a N1/N1c M0 70.3% 
 T2-T3 N2a M0  
 T1-T2 N2b M0  
Stage IIIC T4a N2a M0 46.9% 
 T3-T4a N2b M0  
 T4b N1-N2 M0  
Stage IVA T1-4 Any N M1a 15.2% 
Stage IVB Any T Any N M1b 9.7% 
Note: The staging system is according to the American Joint Committee on Cancer (AJCC) 7th Edition staging system.46 The 5-year 







The only curative treatment for CRC is total resection of the affected colorectal seg-
ment along with all associated locoregional lymph nodes, which could potentially 
harbor lymph node metastasis. Current treatment guidelines involve neo-adjuvant 
chemo- and radiotherapy, surgical resection, and adjuvant chemotherapy. All patients 
are discussed in a multidisciplinary conference comprising surgeons, pathologists, 
radiologists, and medical oncologists. The basis for the optimal patient treatment re-
lies on pre-treatment staging and the distinction between colon and rectal cancer. The 
standard treatment of colon cancer is surgery, combined with adjuvant chemotherapy 
depending on the stage of disease at the time of diagnosis (Figure 7). The treatment 
options for rectal cancers and the treatment options for colon cancer are highly simi-
lar, with the addition of neoadjuvant chemoradiotherapy. The difference in treatment 
between rectum and colon cancer also relies on the difference in embryological 
origin, with the vascular drainage from the rectum going straight to the vena cava, 
and the vascular drainage from the colon going to the portal circulation, rendering 
pulmonary metastasis more common in rectal cancer.  
 
COLORECTAL SURGERY 
Principally, CRC surgery involves the resection of the tumour-bearing bowel seg-
ment, with adequate proximal, distal, and lateral resection margins, central ligation 
and division of the supplying blood vessels, and removal of the attached mesoco-
lon/mesorectum. This type of resection is based on the sharp dissection of distinct 
embryological planes to avoid breaching the visceral layer and the possibility for tu-
mour spread to the peritoneal cavity.50,51 The complete resection (R0) involves the 
aforementioned elements and complete en-bloc removal of the resected bowel.52 
Bowel-continuity is re-established by a sutured or stapled anastomosis. The presence 
of residual tumour is reported as either macroscopic (R2) or microscopic (R1).  
If the circumferential resection margin involvement is below 1 mm, the patient has 
not received radical surgical treatment. If the involved lymph nodes (< 12 lymph 
nodes) are not removed, the resection is also considered incomplete. In both cases, 
post-operative staging cannot be considered optimal. 
Laparoscopic surgery is the approach of choice in the case of uncomplicated cancer 
of the right and left colon, because it offers faster recovery and less morbidity com-
pared to the open approach.53–58 In the case of bulky and advanced colonic lesions, 
laparotomy and subsequent resection is still considered the treatment of choice. 
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Figure 7 Treatment algorithm for non-metastatic colon cancer  
The algorithm is in accordance with the National guidelines in Denmark provided by the Danish Colorectal Cancer 
Group (2017). The distinction between high and low risk stage II colon cancer is based on the risk of recurrence, and 
the associated risk factors are listed in the box “Risk Factors”. Patients > 75 years, patients with WHO performance sta-
tus > 2 due to comorbidity, or patients with MSI tumours should never receive adjuvant chemotherapy regardless of the 
presence of risk factors. Adjuvant chemotherapy is usually based on 5-Flourouracil, oxaliplatin, or capacitabine. 
 
COLORECTAL ONCOLOGY 
Medical treatment of CRC involves the use of cytostatic drugs to induce tumour re-
gression. Current treatment regimens can only be used as supplements for curative 
surgery; otherwise, the usage is only palliative in nature. 
Adjuvant chemotherapy for CRC without metastasis can commence within five 
weeks after surgery or when the patient is fit to receive therapy. The standard treat-




acid (de Gramont). For stage III colon cancer, treatment is based on the combination 
of folinic acid, 5-fluorouracil, and oxaliplatin (FOLFOX), or a combination of cape-
citabine, and oxaliplatin (CAPOX).59,60 For stage III rectal cancer, the choice of treat-
ment depends on the rectal tumour location, with one of the treatment options being 
neo-adjuvant chemo-radiotherapy.61 
For metastatic CRC, treatment is tailored according to the degree of disease dissem-
ination, a pivotal factor being the resectability of the metastasis.62 Resection or ra-
diofrequency ablation (RFA) of solitary liver metastasis provides a strong survival 
benefit in these select patients.63,64 Moreover, molecular biomarkers are utilised in 
the choice of treatment with monoclonal antibodies. One example being tumours har-
bouring an activating mutation in KRAS or NRAS, in which patients will not derive 
benefit from treatment with epidermal growth factor (EGFR) monoclonal antibodies 
such as cetuximab and panitumumab.62 Other types of molecular changes utilised in 
the treatment of metastatic CRC is described in the section on molecular characteris-
tics, below.  
 
FOLLOW-UP 
The aim of follow-up is the detection of local or distant recurrence, metachronous 
colonic lesions, and assessment of late post-treatment morbidity. Intense follow-up 
programmes have led to an improved overall survival by 7-13%.65 However, there is 
still some ambiguity regarding the optimal structure of CRC follow-up programmes, 
and the results of the COLOFOL trial is therefore much anticipated.66 The Danish 
follow-up programme includes colonoscopy three months after surgery (if colonos-
copy was not conducted prior to resection), followed by colonoscopy every five years 
postoperatively (until the age of 75). CT of the thorax and abdomen should be con-
ducted one and three years after diagnosis.  
Preoperative carcinoembryonic antigen (CEA) levels are analysed and utilised as the 
only blood-based biomarker for the detection of completeness of surgery (increased 
preoperative CEA-levels, should normalise after surgery). An increase in post-oper-
ative CEA-levels is used as an indication of disease recurrence, however, with lack-
ing sensitivity.67 The limited sensitivity of CEA makes it unfit for both CRC detection 
and screening.  
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1.2. MOLECULAR CHARACTERISTICS 
The molecular basis for cancer in general, is the inactivation of genes associated with 
cellular regulation and the activation of genes involved in increased cell survival and 
metastatic properties.  
Theodor Boveri already proposed the concept of cancer being a genetic disease in 
somatic cells in 1914, prompted by the works by David von Hansemann.68 Their pi-
oneering efforts were based on aberrant mitosis, chromosome numbers and abnor-
malities in centrosomes, and Boveri even anticipated the era of tumour suppressor 
genes and oncogenes. In 1971, Alfred G. Knudson formulated his two-hit hypothesis, 
considering cancer as a multi-mutational disease, with inherited forms already bear-
ing one of the two hits necessary for cancer formation further emphasising cancer as 
a genetic disease.69 The discovery of proto-oncogenes in cancer cells by Dominic 
Stehelin, J. Michael Bishop, and Harold E. Varmus provided the evidence, that alter-
ations in our own genes can cause cancer formation – the basis for J. Michael Bishop 
and Harold E. Varmus being awarded the Nobel Prize in 1989.70   
 
Figure 8 Timeline of the discovery of cancer related genetic alterations 
A broad overview of the most important findings associating mutational events with carcinogenesis.  
Adapted from Knudson (2001).71 
 
Today, we know that tumours develop from benign to malignant lesions by acquiring 
a series of mutations over time. This multi-step carcinogenesis paradigm relates well 
to the fact that cancer takes several years, even decades, to develop making age, the 
most pertinent risk factor.  
Genome-wide data have shown, that a typical colorectal tumour harbours approxi-




mutation, which provides a selective growth advantage for the tumour cell compared 
to the surrounding normal epithelial cells. The mutations, which confer a selective 
growth advantage, are called drivers, and to date, approximately 120-140 have been 
discovered (~65 oncogenes and ~75 tumour suppressors genes).72,73 Oncogenes are 
usually affected by missense mutations, altering amino acid residues, leading to a 
gain-of-function or non-regulated protein expression (e.g. KRAS, BRAF, and 
SMAD4). Tumour suppressor genes are typically affected by any kind of mutation in 
the coding region, which ultimately disables the protein product (e.g. RB1, TP53, and 
APC). The drivers can be classified into one or more of three distinct cellular pro-
cesses: (i) cell fate, (ii) cell survival, and (iii) genome maintenance. 
Alterations in genes involved in the above mentioned cellular processes, will always 
produce a cancer cell with a selective growth advantage over normal cells. Several 
different genes can result in the same growth advantage, with a large overlap between 
the different cellular processes, making the identification of drivers difficult. Alt-
hough many drivers have been identified, the vast majority of mutagenic alterations 
in human cancers are bystanders. These passengers do not contribute to cancer for-
mation, instead, they constitute the bulk of the somatic alterations in each individual 
tumour. The strict distinction between molecular drivers and passengers remains en-
igmatic, and the subject for vigorous research. 
 
1.2.1. THE GENETIC BASIS FOR COLORECTAL CANCER 
The molecular characteristics of CRC initiation and progression through the ade-
noma-carcinoma sequence, was first described by Eric R. Fearon and Bert Vogelstein 
in 1990.74,75 The adenoma-carcinoma sequence describes the stepwise progression 
from normal to dysplastic epithelium, along with the accumulation of several genetic 
alterations (Figure 9). This accumulation of gene mutations is non-random and initi-
ates colorectal carcinogenesis through the deregulation of pathways that modulate 
cellular differentiation, proliferation, and apoptosis.72 
All CRCs harbour genetic alterations, including single base substitutions, and larger 
structural variations (e.g. aneuploidy).76,77 A detailed description of all the mutational 
events related to CRC is beyond the scope of this thesis; however, some of the most 
important genetic aberrations will be described below. 
The classical description of the multistep genetic model for CRC starts with the in-
activation of APC. APC mutation occur in more than 80% of sporadic CRCs.78 APC 
germline mutation is also responsible for the autosomal dominant inherited FAP syn-
drome associated with multiple colorectal adenomas.79 APC inactivation is followed 
by two other frequent mutations, KRAS and BRAF. Mutation of KRAS/BRAF leads to 
an enhancement of the gene product, stimulating cellular growth through the 
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MAP/ERK pathway. KRAS is mutated in 33% and BRAF in 10% of CRCs.80,81 The 
KRAS/BRAF protein is downstream of EGFR, making treatment with monoclonal 
antibodies against EGFR redundant in mutant tumours. Other additional mutations 
resides in the TGF-β (SMAD4), PIK3CA, and TP53 pathways along with loss of het-
erozygosity and aneuploidy.82 Indeed, these associations of chromosomal instability 
are seen in ~85% of invasive CRC.77 Other molecular alterations are simplistically 
illustrated in Figure 9. 
 
Figure 9 The adenoma-carcinoma sequence  
Colorectal carcinogenesis develops through a series of genetic alterations, involving oncogenes (e.g. BRAF, CDC4, 
KRAS, and SMAD4) and tumour suppressor genes (e.g. APC, BAX, and TP53). The chromosomes most frequently de-
leted include 5q, 17q, and 18q. 
 
CRCs harbouring a deficient mismatch repair (MMR) system regardless of origin 
account for 15-20% of CRC cases.83 The MMR system is responsible for the surveil-
lance, and correction of errors introduced in microsatellites (interspersed repetitive 
elements throughout the human genome – prone to mutations). The main MMR genes 
are MLH1, MSH2, MSH6, and PMS2, and downregulation of either of these, will 
infer microsatellite instability (MSI). HNPCC patients with Lynch syndrome have an 
autosomal dominant germline defect in one of the MMR genes causing their predis-
position to CRC (described above).84 CRCs with MSI are associated with right-sided 
tumours, with an improved prognosis compared to sporadic tumours.85,86 Moreover, 
MSI CRCs are more susceptible to treatment with PD1-antibodies.87 Modes of MSI 
also involve epigenetic inactivation of MLH1 via promoter hypermethylation. This 
mode of tumour development due to hypermethylation is the focus of this thesis and 
described in further detail below. 
CRCs arising in the proximal and distal colon appear to arise from distinct molecular 
pathways, reflecting the physiological differences between the two bowel segments. 
These molecular differences may explain differences in morphology (increased pro-




1.2.2. HYPERMETHYLATION AND COLORECTAL CANCER 
Epigenetics is the study of heritable changes in DNA expression, without an under-
lying change in the DNA sequence. DNA methylation and histone modifications are 
the fundamental elements in epigenetics, and each function to adapt the chromatin, 
and hence genomic expression.88 These changes are inherently reversible, and can be 
altered by multiple environmental factors and different disease states, making them 
an interesting field for the development of epigenetic therapies.89 DNA methylation 
and histone modifications are closely linked molecular phenomena, however, only 
DNA promoter hypermethylation, will be described in the section below. Stephen B. 
Baylin and Peter A. Jones (2016), elegantly and thoroughly describe histone modifi-
cations and other epigenetic processes in relation to cancer.89 
 
Figure 10 The effect of DNA hypermethylation on transcriptional activity  
The promoter region of tumour suppressor genes is normally hypomethylated, and different histone modifications en-
sure a stable open chromatin structure (euchromatin) making transcription possible. In the malignant transformation of 
epithelial cells, the promoter regions become densely methylated, and different histone modifications makes the chro-
matine more tightly packed (heterochromatin) leading to transcriptional repression. 
 
DNA methylation involves the addition of methyl groups to cytosine preceding a 
guanine (CpG). Cytosine methylation in the CpG dinucleotide motif is essential for 
normal mammalian development, X-chromosome inactivation, and genomic imprint-
ing.90 During embryological development, the DNA of the embryo is first subject to 
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an initial wave of demethylation, after which (the eight-cell stage) the embryo DNA 
receives a cascade of de novo methylation.  The target for methylation is the 5’-car-
bon, and the following dinucleotide is denoted 5-methylcytosines. Methylation of the 
5’-carbon is catalysed by one or more of the group of enzymes called DNA methyl-
tranferases (DNMTs) using a methyl-group from S-adenyl methionine.91 CpGs are 
found genome-wide, however, not at a frequency, which would otherwise be ex-
pected by chance. They often cluster in regions called CpG islands, and global CpG 
island hypomethylation and regional hypermethylation is part of nearly all human 
malignancies.92,93 CpG island methylation at key sites in the DNA promoter regions 
have been shown to lead to decreased transcriptional expression, and thereby effec-
tively hindering tumour suppressor function. This mechanism is thought to originate 
based on the blockage of transcription factors and conformational changes in the 
chromatin structure (Figure 10).94,95 Several studies have suggested, this hypermeth-
ylation associated gene silencing, however, the association is not constant. Recent 
epigenome-wide association studies (EWAS) have shown, that the inverse correla-
tion between DNA hypermethylation and gene expression might be as low as 40%.96 
Nevertheless, it is still widely accepted that promoter hypermethylation infers de-
creased transcriptional activity. Previous studies suggest that the regulation of DNA 
methyltransferase 1, which possesses de novo methylation activity for CpG-islands, 
becomes dysregulated during colorectal carcinogenesis.97,98 However, increased pro-
moter hypermethylation in cancer is not merely a result of a transcriptional deregu-
lation in the three known DNMTs.99 The underlying cause for deregulation in pro-
moter methylation remains unknown. 
The evaluation of gene hypermethylation status has revolved around tissue studies. 
Historically, the identification of putative methylation biomarkers has been con-
ducted using candidate gene approaches. However, advancing genome-wide technol-
ogies have significantly increased the current knowledge on the scope of DNA meth-
ylation changes in CRC.  In normal colonic cells, various patterns of DNA methyla-
tion exist based on anatomical location, embryological origin (midgut vs. hindgut), 
gender, and patient age.100 Generally, DNA of these normal cells exhibit a low degree 
of methylation. Colorectal tumour cells are very different in this regard. These cells 
are characterised by methylation of various tumour suppressor genes and intra-
genomic hypomethylation of repetitive elements (e.g. LINE1).101–103 Hypermethyla-
tion is an early event already seen in adenomas and aberrant crypt foci (e.g. CDKN2A) 
and associated with poor survival in stage II and III CRC.104,105  
The number of methylated gene promoter regions related to CRC initiation and pro-
gression is enormous.106 Tissue studies have suggested that CpG island hypermeth-
ylation might be associated with a distinct CRC subtype termed the CpG island meth-
ylator phenotype (CIMP).107–109 CIMP has been characterised by a high frequency of 
methylation at key genomic sites, and associated with right sided tumours, a high 




type.110 CRC tumours with CIMP and tumours with a high degree of mutations (chro-
mosomal instability), have been shown to be inversely correlated, leading to the un-
derstanding that there may be three distinct subtypes of CRC following three distinct 
molecular pathways; namely the chromosomal instability pathway, the MSI pathway, 
and the CIMP pathway. The definition of CIMP currently relies on the works by 
Weisenberger et al. (2006) who identified a robust five gene panel, currently used to 
define CIMP tumours.108,111 However, the cause or the mechanism for CIMP has still 
to be identified, and one study has even postulated, that CIMP merely is a statistical 
artefact.112 Moreover, a recent study found that CIMP did not have any impact on the 
survival of CRC patients.113 The sensitivity of the panel therefore remains to be val-
idated.114  
The candidate gene-approach studies and EWAS show, that there is a marked differ-
ence in DNA promoter methylation between cancer types.99 Each cancer type may 
therefore harbour its own hypermethylation signature. A recent study even showed, 
that CRCs harbour more aberrant DNA hypermethylation compared with somatic 
mutations.115 Since methylation patterns are already altered in colorectal adenomas, 
this promotes their utilisation as biomarkers for CRC detection.115,116 However, it is 
still not known, if DNA hypermethylation is a driver or passenger alteration in the 
initiation and progression of CRC. 
 
1.2.3. THE CONSENSUS MOLECULAR SUBTYPES  
The amount of data from recent GWAS and studies on genome expression, have in-
creased in recent years. These studies have focused on improving our understanding 
of CRC, and primarily aimed at identifying molecular subgroups to enable improved 
diagnostics, stratification according to prognosis, and response to adjuvant chemo-
therapy. The combined effort to understand the molecular biology of CRC has led to 
the characterisation of CRC by means of the consensus molecular subtypes (CMS 1-
4).117 Each subtype has a set of distinct genomic and epigenomic traits. Moreover, 
their mode of pathway enrichment is relatively unique. Proximal tumours with CMS1 
is characterised by hypermutation and hypermethylation, whereas CMS2-4 are more 
closely linked to an increase in chromosomal instability. These subtypes could po-
tentially serve as adjuncts in treatment decision making. Proximal CMS1 and CMS3 
tumours have a decreased expression of EGFR ligands, whereas CMS2 reveals an 
overexpression of EGFR ligand, prompting sensitivity for EGFR monoclonal anti-
bodies (e.g. cetuximab). Even though it was developed using multiple datasets com-
prising data from 4.151 CRC patients, the consensus molecular subtypes, have yet to 
prove that they correctly stratify patients in clinically relevant subgroups. A recent 
study has even proposed another model (consisting of three cancer cell archetypes 
and five tumour archetypes) refining the characterisation of CRC.118 This includes 
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the dARE archetype (a stratification of CMS2) which is associated with a higher bac-
terial read count than other chromosomally instable tumour samples. This illustrates, 
that characterisation of human tumours is complex, probably due to tumour hetero-
geneity, laboratory techniques, imperfect assays, and interpretation of the vast 
amounts of data. Whether or not these molecular characterisation patterns have any 
clinical utility, remains to be elucidated.  
 
1.2.4. CIRCULATING MOLECULAR BIOMARKERS 
Extracellular nucleic acids was first described by Mandel and Metais in 1948.119 Sub-
sequently, Leon et al. (1970) showed that the level of circulating cell-free DNA was 
increased in cancer patients.120 Since then, elevated levels of circulating cell-free 
DNA have been observed in nearly all cancer types (e.g. breast, lung, and ovarian 
cancer), and a number of other non-malignant disease entities.121,122 
 
Figure 11 Circulating cell-free DNA  
DNA is released by manner of necrosis, apoptosis, phagocytosis, and active secretion. DNA is shed as both single and 
double stranded DNA with an approximate length of 160-180 base pair. Circulating tumour DNA is even more frag-
mented with an approximate length < 145 base pair. Membrane blebbing leads to the release of circulating DNA in 
apoptosis. Circulating DNA related to exosomes are structurally associated with the membrane (> 2,500 base pair), or 




Circulating cell-free DNA can be analysed using the same molecular methods, as 
DNA obtained through tissue biopsies. This makes it possible to detect various tu-
mour related mutations, polymorphisms, and aberrant hypermethylations. One of the 
challenges in analysing cell-free tumour derived genomic alterations, is the scarcity 
of these fragments. The number of cell-free tumour DNA fragments has been shown 
to be less than 10 per 5 ml plasma for stage I CRC, and detecting these fragments in 
a larger amount of normal DNA is inherently difficult.123  
DNA from malignant cells is highly fragmented with a molecular size smaller than 
145 base pairs. Assays used for the detection of these small amounts of DNA needs 
to be highly sensitive in order to detect the mutational changes or various degrees of 
hypermethylation. Current methods for the DNA methylation analysis are described 
in the following section. 
 
1.2.5. METHODS FOR HYPERMETHYLATION ANALYSIS 
A large number of strategies for DNA methylation analysis exists, and have been 
used to describe different methylation biomarkers.124 These methods can broadly be 
classified into four main categories: 
i. Restriction enzyme digestion 
ii. Affinity-based analysis 
iii. Bisulphite modification 
iv. Direct sequencing 
The method of choice is very much dependent upon the hypothesis of the individual 
study being performed (e.g. the evaluation of putative disease methylation sites or 
discovery of novel areas of aberrant DNA methylation). This is due to the different 
strengths and weaknesses of each methodological. Table 3 provides a short descrip-
tion of the methods currently available for methylation analysis. 
The cornerstone in the analysis and validation of aberrantly methylated DNA has 
been bisulphite conversion and subsequent analysis by polymerase chain reaction 
(PCR). This method relies on the differential reaction of methylated and un-methyl-
ated cytosine with the reagent. Un-methylated cytosine undergo deamination con-
verting them into uracil, whereas, methylated cytosine residues remain intact, creat-
ing methylation-dependent sequence differences in the genomic DNA (Figure 12). 
Sequence variants at a particular locus can subsequently be analysed using PCR am-
plification targeting bisulphite converted DNA or microarray based technologies. 
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Table 3 Methods for DNA methylation analysis 
 Description Advantages Limitations 
Restriction enzyme digestion Use methylation-sensitive 
enzymes, with different af-
finities for cytosine methyla-
tion status. 
The restriction enzymes, 
Mspl and HpaII, both recog-
nise the same sequence 
(CCGG), however, with 
their cleavage capabilities 










Limited to enzyme 
digestion sites 
Not well suited to 
distinguish moder-




Affinity based analysis Use shearing to generate 
random DNA fragments fol-
lowed by denaturation and 
immunoprecipitation of sin-
gle stranded DNA fragments 
with monoclonal anti-5-
methylcytosine antibodies. 
The isolated DNA fragments 
are then enriched and ampli-
fied using PCR, microarray, 
or sequencing based tech-
nologies.  
 
Fast and reliable as-
sessment of mean 
methylation levels of 






cially available and 




Limited by the sen-
sitivity and speci-
ficity of the anti-
body 
Provides no infor-





Bisulphite modification Use treatment with bisul-
phite to generate a differ-
ence in the DNA sequence. 
It relies on the differential 
reaction of methylated cyto-
sines versus un-methylated 
cytosines with bisulphite. 
The conversion can be de-
tected using various meth-
ods combined with PCR, 




Allows for global DNA 
methylation analysis 
Most widely accepted 
and utilised method 
When combined with 
PCR it is rapid, simple, 
and cheap 
Significant degra-
dation of DNA dur-
ing conversion 
Incomplete conver-









gies for global 
DNA analysis 
 
Direct sequencing Use the time difference be-
tween base incorporations 
(the inter-pulse durations) or 
electrolytic current signals 
to detect aberrantly modified 
nucleotides. 
Allows for global DNA 
methylation analysis 
Does not rely on bisul-
phite conversion 
 
The accuracy for 5-
methylcytosine may 
be limited, due to 
weak kinetic sig-
nals or low signal 
resolution 
Labour intensive  
Sequencing bias 
 
Note: Description of the four overall methods for DNA methylation analysis. Most of the methods listed above are thoroughly re-





Methylation specific PCR is the most utilised method for locus-specific bisulphite 
modification analysis, with a reliable application in numerous clinical studies.127–132 
A number of variations for methylation specific PCR exist, each being suitable for a 
number of different research applications. In methylation specific PCR, the bisulphite 
modified DNA is subsequently amplified using primer sets and a fluorescent probe 
specific for the methylated sequence of interest. A range of modifications have been 
made to the methylation specific PCR technology, however, the overall principle re-
mains the same.133–138 
 
Figure 12 Bisulphite treatment of cytosine and 5-methylcytosine 
Cytosine is converted into uracil through aromatic sulphonation and deamination. The 5-methylcytosines are not con-
verted during bisulphite treatment. The bisulphite treatment creates a difference in the DNA sequence (box) amenable 
for detection by PCR based methods. 
 
One of the major benefits of bisulphite based assays, is that the method only relies on 
small amounts of sample DNA, and the high-throughput capacity of most of the PCR 
based assays.138 
One of the major drawbacks in bisulphite-based methods is the massive degradation 
of DNA rendering less DNA for subsequent PCR analysis. Moreover, incomplete 
conversion could lead to erroneous interpretations.139 Another drawback in using 
PCR based methods is the loss of information, since only one CpG-island can be 
analysed at any one time. It is therefore not possible to make inference about the 
methylation status of the whole promoter region. Lastly, as with other techniques 
relying on PCR, false positives can arise if primers are of poor quality or used at 
incorrect temperatures.  
The gold standard for evaluating DNA methylation remains bisulphite conversion 
followed by sequencing, because it enables the base-pair resolution of CpG methyl-
ation.140 However, the procedure is costly and time-consuming, generating vast 
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amounts of data, necessitating complex bioinformatics (base-calling), making inter-
pretation difficult. 
The method utilised through this thesis, is based upon an optimised methylation spe-
cific PCR protocol described by our group.141 The method relies on a rapid bisulphite 
conversion, rendering the method more readily applicable. Methods used in previous 
studies, and most commercially available kits are very time consuming, relying on 
treatment with bisulphite for 4-18 hours before subsequent PCR or sequencing anal-
ysis.142 The method employed by our group takes advantage of deamination at a 
higher temperature to ensure complete bisulphite conversion with a yield of nearly 
60% DNA post treatment.143,144 A recent review of four commercial kits also suggests 
that our method is more than comparable as these methods produced a DNA recovery 
ranging from 33.2% to 55.0%.145 
The method uses MEST as a reference gene for methylation. MEST is useful as a 
naturally occurring model system, due to the fact that MEST is maternally imprinted 
rendering only one allele methylated.146 This type of hemimethylation makes it pos-
sible to ensure the correct assessment of the effect of methylation changes in other 
putative methylation biomarkers.141 All primers and probes are specific for methyla-
tion and synthesised in-house. We used hypermethylation specific molecular beacons 
for the real-time PCR assay.  
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CHAPTER 2. AIMS AND SCOPE 
This thesis is based on the epigenetic foundation from which cancer develops. The 
number of studies addressing molecular changes in human malignancies have ex-
ploded in recent years, and the characterisation of solid cancers in general and CRC 
in particular expands using improved molecular methods. Hence, the development of 
novel biomarkers for all types of human malignancies is an extremely rapid process. 
However, not many of these putative biomarkers are currently used in clinical prac-
tice. This lack of biomarker utilisation is primarily due to a lack of performance in 
subsequent validation studies or the scarcity of replication studies in general. Alas, 
the efficacy of cell-free DNA hypermethylation as biomarkers for CRC lacks suffi-
cient evaluation. 
The aims of the current thesis were: 
1) To conduct a systematic review of cell-free hypermethylated DNA as 
a biomarker for CRC. The review would serve two purposes:  
 
i. To give a broad overview over the studies conducted so far.  
ii. To select hypermethylated regions for further analysis. 
 
2) To evaluate the potential of hypermethylated cell-free DNA in plasma 
for CRC detection. 
 
3) To evaluate the value of hypermethylated cell-free DNA in plasma 






    
CHAPTER 3. METHODS 
The methods for each of the three aims listed above, will be described in detail in this 
section. First, a description of the selection of gene promoter regions to be evaluated 
as potential predictive biomarkers for CRC. Secondly, a description of the study pop-
ulations for each study, followed by a description of the stepwise hypermethylation 
analysis. Lastly, the data handling and statistical analyses will be elaborated. 
 
3.1. LITERATURE STUDY 
The focus of this thesis was the evaluation of hypermethylation biomarkers for CRC 
detection and prognostication. These were selected through a comprehensive review 
of the current literature.  
Eligible studies were all articles where cell-free DNA was analysed for methylation 
of putative CRC promoter regions. Cell-free DNA has been evaluated in both stool 
and blood samples, for the detection of CRC. We chose to include these stool based 
hypermethylation studies to make the most comprehensive analysis of hypermethyl-
ation biomarkers for CRC detection. The literature search also included all the studies 
on tumour biopsies to ensure the completeness of the literature search.  
Embase, Web of Science, and Medline databases were searched, using the following 
terms: DNA methylation, CpG islands, tumour sample, stool sample, blood, serum, 
plasma, PCR, microarray analysis, genome sequencing, biopsy, and blood analysis 
(updated September 2015).  
Studies were considered if they analysed one or more hypermethylated gene promoter 
regions from stool or blood samples. All studies were included, regardless of size or 
analytical method. Studies considering solely, tumour biopsies, cell lines, and animal 
models, were subsequently excluded along with studies written in languages other 
than English.  
For the subsequent hypermethylation analysis we chose biomarkers with the capabil-
ity to distinguish early stage CRC patients from healthy control individuals. Moreo-
ver, we included hypermethylation markers found in other types of solid cancers (e.g. 
pancreatic cancer). The names and known functions of the 30 genes analysed for 
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3.2. STUDY POPULATION 
The thesis is based on the analysis of blood samples from a previous study conducted 
at the Department of Gastrointestinal Surgery, Aalborg University Hospital. 
Between October 2003 and November 2005, 314 consecutive CRC patients were 
evaluated as participants in a study of pre- and postoperative venous thromboembo-
lism. These patients were admitted for intended curative surgery and had blood sam-
ples drawn before any kind of treatment. Patients were excluded if they had any pre-
vious or concomitant cancer of any origin (within three years), known congenital 
thrombophilia, thromboembolic events within three months before treatment, con-
nective tissue disease, severe acute infectious disease, stroke/neuro-surgery within 
six months before treatment, pregnancy, endocarditis, or ongoing anticoagulant treat-
ment.147 These patients would constitute the case group in the analysis of DNA hy-
permethylation as a biomarker for CRC detection. Furthermore, these patients were 
followed with regular intervals up to five years after inclusion. These patients would 
also be utilised in the assessment of circulating hypermethylated DNA as biomarkers 
for CRC prognosis. 
During the same study period, blood samples from 143 patients referred for colonos-
copy on suspicion of CRC were also included in the biobank. The colonoscopy re-
vealed no sign of lower GI malignancy. These patients constituted the control group. 
 
3.3. ETHICAL CONSIDERATIONS 
All patients have provided written informed consent for the initial study. The North 
Denmark Region Committee on Health Research Ethics (N-20140064) and The Dan-
ish Data Protection Agency (2008-58-0028) have approved the conduction of the cur-
rent study. The study was registered at ClinicalTrials.gov (NCT02928120). 
 
3.4. BLOOD SAMPLING 
All blood samples were obtained before colonoscopy in the control group and before 
any kind of treatment among CRC patients. Cubital venepuncture was used following 
the European Concerted Action on Thrombosis manual.148 Sampling was conducted 
in EDTA tubes, centrifuged for 20 minutes at 4 °C and the plasma supernatant was 





3.5. HYPERMETHYLATION ANALYSIS 
The detection of hypermethylated cytosines can be made using a variety of different 
molecular methods already described. The method used in this study is based on 
methylation specific real time PCR using a rapid bisulphite protocol.141 The individ-
ual analytical steps are described below (a schematic version of the individual steps 
in the hypermethylation analysis is presented in Supplementary figure 1). The name 
and known function of each individual gene is provided in Supplementary table 1. 
 
3.5.1. SAMPLE PREPARATION 
We extracted sample nucleic acids from 350-1,000 μl of EDTA plasma using the 
easyMagTM (NucliSens® [bioMérieux SA, France]) according to the manufacturers’ 
instructions. The extracted nucleic acids were subsequently eluted in 35 μl elution 
buffer (NucliSens® [bioMérieux SA, France]).  
In order to quantitate the amount if DNA in each patient sample, we used five μl of 
the extracted DNA. We subsequently mixed the remaining 30 μl of purified nucleic 
acids with 60 μl of deamination solution, deaminated for ten minutes at 90 °C, fol-
lowing a purification step, and eluted in 25 μl 10 mM KOH.  
 
3.5.2. PREAMPLIFICATION 
The deaminated nucleic acids were then subject for a pre-amplification procedure in 
order to expand the limited amounts of DNA present in each patient sample, using 
the outer primers (Supplementary table 2 and 3).  
The reaction buffer (25 μl) consisted of PCR buffer, 13 μM MgCl2, 0.6 mM dNTP, 
250 nM of each outer primer, 1.5 U Taq polymerase (MyTaqTM [Bioline®, Taunton, 
MA, USA]), and 0.3 U Cod Uracil-DNA Glycosylase (Cod UNG [ArcticZymes®, 
Tromsoe, Norway]). We distributed the first-round reaction mix to individual 200 μl 
PCR tubes, which were incubated for five minutes at 37 °C, followed by 95 °C for 
five minutes, and actively cooled to room temperature. Thereafter, we added 25 μl of 
purified deamination product to each tube, and performed the PCR reaction for 20 
rounds (92 °C for 15 seconds, 55 °C for 30 seconds, and 72 °C for 30 seconds). 
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3.5.3. REAL-TIME PCR 
The product from the pre-amplification procedure was used for the real-time PCR 
reaction using the inner primers and probes listed in Supplementary table 2 and 3. 
For each individual reaction, we distributed 10 μl buffer containing 0.4 μM inner 
primers and probes in 30 individual wells in a 96 well PCR plate. We added 10 μl of 
the first round PCR product to 710 μl preincubated reaction mix (37 °C for five 
minutes and 95 °C for 10 minutes) containing PCR buffer, 250 μM dNTP, 10 μM 
MgCl2, 8 U Taq polymerase (BIOTAQTM [Bioline®, Taunton, MA, USA]), and 0.8 
Uracil-DNA Glycosylase (Invitrogen®, Waltham, MA, USA). Twenty μl of reaction 
mix was then added to each of the 30 wells containing primers and probes. Real time 
PCR was conducted for 45 rounds (94 °C for 15 seconds, 55 °C for 30 seconds, and 
72 °C for 30 seconds). 
All PCR curves were analysed using the MxProTM, Mx3005P Quantitative PCR Soft-
ware (Stratagene® [Agilent Technologies®, Santa Clara, CA, USA]) at a fluorescence 
threshold of 500 dR.  
 
3.6. STATISTICAL ANALYSES 
The evaluation of the individual hypermethylated DNA promoter regions as bi-
omarkers for CRC detection and prognostication was done using two distinct analyt-
ical methods. The methods employed are described in detail according to each study. 
Each study is exploratory in nature.  
In both studies, each hypermethylated biomarker was regarded as positive, if a signal 
was registered during PCR amplification. The amount of information lost due to this 
dichotomisation was evaluated using a stratification method, comparing the cycle 
threshold (Ct) value between CRC patients and controls. The median cell-free DNA 
levels were compared between CRC patients and healthy controls using the Wil-
coxon-Mann-Whitney test, and between CRC stages using the Kruskal-Wallis test. 
Comparisons of the median number and range of cell-free hypermethylated promoter 
regions were made using the Wilcoxon-Mann-Whitney test.  
STATA® V.13.1 (StataCorp. 2013. Stata Statistical Software: Release 13. College 





3.6.1. COLORECTAL CANCER DETECTION 
To evaluate the utilisation of hypermethylated DNA fragments as biomarkers for 
CRC, we constructed a multivariable logistic regression model. The patients used for 
this analysis were patients with biopsy verified CRC and colonoscopy verified 
healthy controls. The stepwise model development and subsequent validation is pre-
sented below: 
Outcome and predictor variables 
The outcome variable was the presence of CRC. The potential predictor variables 
were each individual cell-free hypermethylated promoter region, CEA levels (>5 
ng/ml), sex, and age. Each variable was handled as a dichotomous variable. All pa-
tients in the two groups were used in the analysis. The study was exploratory in na-
ture, and as such, no sample size calculation was conducted. 
Model development 
Each of the potential hypermethylated predictor variables were analysed using uni-
variate logistical regression. Each predictor variable reaching a significance level of 
p ≤ 0.3 were included in the subsequent stepwise logistic regression analysis. The 
models were evaluated using receiver operating characteristics (ROC) curves and by 
calculating the area under the ROC curve (AUC). The model deemed most promising 
was then evaluated and each interaction between the potential predictor variables was 
estimated.  
In order to ensure the correct selection of variables and assess the impact of separa-
tion issues in the model building process, we computed a penalised regression model 
using Firth’s method with backwards selection.149 Hosmer-Lemeshow’s goodness of 
fit test was used to assess the final model.  
Leave-pair-out cross validation was used to assess the inherent problem of model 
overfitting, and the optimism corrected AUC was presented to evaluate the predictive 
performance of the final model.  
The predictive performance of the model was evaluated using all stage patients and 
subsequently evaluated in early stage CRC patients (stage I and II).  
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3.6.2. COLORECTAL CANCER PROGNOSIS 
The study on the prognostic utility of cell-free hypermethylated DNA in plasma was 
divided into two parts: (i) a cross-sectional study on the correlation between the num-
ber of cell-free hypermethylated DNA promoter regions and the primary stage of 
CRC at the time of diagnosis, and (ii) a cohort study evaluating the impact of cell-
free hypermethylated DNA on patient survival. 
Outcome and predictor variables 
The outcome variable for the cohort study was time from inclusion to death (or cen-
soring). The potential prognostic variables were the 30 hypermethylated promoter 
regions previously described, pre-treatment CEA levels, along with sex and age at 
the time of diagnosis. The potential prognostic variables were handled as dichoto-
mous variables (hypermethylated/un-methylated). CEA was considered positive if 
the level was above 5 ng/ml for non-smokers and above 10 ng/ml for smokers. Sex 
was handled as a categorical variable and as a continuous variable.  
Survival analysis 
As described in the introduction, stage is the universal predictor for survival among 
CRC patients. The number of hypermethylated promoter regions were therefore cor-
related to the primary stage of CRC. The non-parametric Wilcoxon-Mann-Whitney 
test was used to evaluate if the number differed between high and low stage or TNM 
classification (T3/4 vs T1/2, N1/2 vs N0, M1 vs M0). 
Initially we screened each potential prognostic variable for their individual impact on 
patient survival using univariable cox-regression analysis. Using a significance level 
of p<0.01 we selected the potential prognostic variables to be analysed further in a 
multivariable Cox-regression model. In addition, the model incorporated the co-var-
iables sex, age, pre-treatment CEA-levels, and primary CRC stage. 
The Kaplan-Meier method was used to depict the association between cell-free hy-
permethylated promoter regions in plasma and patient survival. 
Recurrence analysis 
The risk of recurrence was evaluated using the data from inclusion on cell-free DNA 
hypermethylation. A competing risk analysis was conducted to evaluate if the number 
of hypermethylated DNA fragments measured at inclusion could predict disease re-
currence. The Aalen-Johansen estimator was used to compute the cumulative inci-
dence plot, and the pseudo-observation method was used to estimate the risk and the 
risk ratio (RR) of recurrence three years after inclusion.150  
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This section will provide the reader with an overview of the results from the three 
studies performed. Moreover, the section evaluating the prognostic utility of cell-free 
hypermethylated DNA includes and their impact on CRC recurrence. The papers are 
appended as the final part of the thesis. 
 
4.1. LITERATURE STUDY 
To construct a prediction model for CRC detection and subsequent evaluation of the 
prognostic utility, a systematic literature search was conducted. This was to identify 
hypermethylated DNA fragments suggested relevant as biomarkers in the setting of 
CRC. The focus was putative hypermethylated promoter regions already evaluated 
in tumour remote media such as stool or blood samples. 
 
Figure 13 Flowchart for article selection  
Search strategy in PubMed: (((((((((((tumor) OR stool sample) OR blood) OR serum) OR plasma)) AND ((((real time 
pcr) OR microarray analysis) OR genome sequencing) OR biopsy))) OR blood analysis)) AND Colorectal Neoplasms) 
AND ((DNA Methylation) OR CpG Islands) 
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We identified 3,520 potential articles in the different databases. Reviewing titles and 
removing duplicates left 1391 articles. Each abstract from the 1,391 articles was then 
reviewed leaving 74 articles; 43 analysing circulating DNA in blood samples and 31 
analysing cell-free hypermethylated DNA in stool samples (Figure 13). 
Most of the studies were characterised by few study participants. Only two large scale 
cross sectional studies have evaluated the performance of hypermethylated DNA 
fragments as biomarkers for CRC detection in stool and blood samples.151,152 Tables 
4 and 5 include the sensitivity and specificity for CRC, according to the individual 
gene promoter regions analysed.  
Some biomarkers have been evaluated for their ability to detect early stage CRC and 
even precancerous lesion (APC, NEUROG1, RASSF1A, RASSF2A, SDC2, SEPT9, 
and THBD). 153–159 Albeit, the sensitivities for the individual markers for stage I CRC 
is rather modest (the sensitivity of APC, and NEUROG1 was below 60% for stage I 
and II CRC), the biomarker SDC2 reached a sensitivity of 92.3% for stage I CRC.154 
It therefore seems likely, that circulating hypermethylated DNA fragments could be 
used in blood based screening for CRC. 
The biomarker, which has been subject to the most vigorous investigation, is SEPT9. 
SEPT9 was identified from the assessment of >600 biomarker candidates.160 Subse-
quently, the biomarker has been evaluated in numerous studies, with promising re-
sults.155,161–167 However, the evaluation in a screening population only revealed a sen-
sitivity of 48.2% at a specificity of 91.4%.151 A recent study analysing a cohort of 
Danish CRC screening patients (published after the publication of our literature re-
view) also revealed that the SEPT9 assay is readily affected by the presence of arthri-
tis and diabetes.168 Moreover, age was associated with assay positivity, regardless of 
the presence of CRC. However, the biomarker still shows some promise as shown by 
a study by Jin et al. (2015).169 They found that the SEPT9 assay had a sensitivity of 
74.8% at 87.4% specificity, compared to iFOBT with a sensitivity of 58.0% at 82.4% 
specificity. Interestingly, the CRCs “missed” by each test were not the same, and the 
authors suggest a combination of the two for future CRC screening. 
SEPT9 has also been utilised as part of a biomarker panel (constituting ALX4, SEPT9, 
and TMEFF2) for CRC detection rendering a sensitivity of 81% at 90% specificity.170 
Moreover, the combination of SEPT9 and TAC1 had a sensitivity for stage I CRC of 
73.1% at 92.3% specificity.155 This favours the utilisation of multiple hypermethyl-




Table 4 Blood-based hypermethylation biomarkers in colorectal cancer 
Gene Specimen Sensitivity, % (n) Specificity, % (n) Method 
ALX4 Serum 83.3% (25/30) 70.0% (21/30)a qMSP 
ALX4 Serum 46.6% (21/45) 66.3% (11/16) qMSP 
ALX4 Plasma 47.8% (87/182) 93.5% (159/170) qMSP 
APC Serum 6.1% (3/49) 100% (41/41)b qMSP 
APC Plasma 56.6% (34/60) 86.0% (86/100)c qMSP 
CDH1 Serum 17.6% (3/17) 100% (10/10) MSP 
CDH1 Plasma 60.0% (36/60) 84.0% (84/100)c qMSP 
CCND2 Plasma 96.7% (29/30) 36.7% (11/30) MA 
DAPK1 Plasma 50.0% (30/60) 74.0% (74/100)c qMSP 
FHIT Plasma 50.0% (30/60) 84.0% (84/100)c qMSP 
HLTF Serum 32.7% (16/49) 92.7% (38/41)b qMSP 
MLH1 Serum 42.9% (21/49) 97.6% (40/41)b qMSP 
NEUROG1 Serum 55.5% (25/45) 81.3% (13/16) qMSP 
CDKN2A Serum 26.9% (14/52) 100% (44/44)d MSP 
CDKN2A Serum 70.6% (12/17) 100% (10/10) MSP 
CDKN2A Serum 6.6% (14/211) 100% (20/20)e qMSP 
RASSF1A Serum 23.5% (4/17) 100% (10/10) MSP 
RASSF1A Plasma 93.3% (28/30) 53.3% (16/30) MA 
RASSF1A Serum 28.9% (13/45) 90.0% (81/90)f MSP 
RUNX3 Serum 64.7% (11/17) 100% (10/10) MSP 
RUNX3 Serum 41.5% (27/65) 90.0% (55/60)g MSP 
SDC2 Serum 87.0% (114/131) 95.2% (119/125) qMSP 
SEPT9 Plasma 72.0% (90/125) 89.6% (164/183) MSP 
SEPT9 Plasma 68.9% (62/90) 89.0% (138/155) MSP 
SEPT9 Serum 46.6% (21/45) 81.3% (13/16) qMSP 
SEPT9 Plasma 90.0% (45/50) 88.3% (83/94) MSP 
SEPT9 Plasma 95.6% (88/92) 84.8% (78/92) MSP 
SEPT9 Plasma 74.7% (136/182) 96.0% (164/170) qMSP 
SEPT9 Plasma 50.9% (27/53) 91.4% (1331/1457)h qMSP 
SEPT9 Plasma 74.8% (101/135) 87.4% (298/341)i qMSP 
SFRP2 Serum 66.9% (113/169) 93.7% (59/63)j MSP 
SMAD4 Plasma 52.0% (31/60) 64.0% (64/100)k qMSP 
TFPI2 Serum 18.1% (39/215) 100% (20/20) qMSP 
THBD Plasma 70.7% (53/75) 80.3% (53/66)l qMSP 
TMEFF2 Plasma 70.9% (129/182) 95.2% (162/170) qMSP 
VIM Serum 31.1% (14/45) 62.5% (10/16) qMSP 
Note: References for the individual studies are provided in the appended article. Unless otherwise specified, the control group was only 
specified as healthy. MSP = Methylation-specific PCR, qMSP = Quantitative methylation-specific PCR, MA = Microarray analysis. 
aThe control group included 15 patients with normal colons and 15 patients with low-grade inflammation or diverticulosis 
bThe control group included 41 patients with colonoscopy-verified healthy controls. 
cThe control group included 40 patients with adenomatous colorectal polyps of low-grade dysplasia. 
dThe control group included 37 patients with adenomatous colorectal polyps of low-grade dysplasia. 
eThe control group included 20 patients without malignancy and healthy controls. 
fThe control group included 30 patients with benign gastric disease, 30 patients with benign colorectal disease, and 30 healthy controls (not otherwise specified). 
gThe control group included 20 patients with benign oesophageal disease, 20 patients with benign gastric disease, and 20 patients with benign colorectal disease. 
fThe control group included 938 patients with no evidence of disease, 210 patients with non-advanced adenomas, and 315 patients with high-grade dysplasia, villous or ≥1 cm non-villous histology. 
iThe control group included 169 patients with adenomas, 81 with hyperplastic polyps, and 91 colonoscopy-verified healthy controls. 
jThe control group included 63 patients with benign colorectal adenomas. 
kThe control group included 40 patients with adenomatous colorectal polyps and 60 healthy controls. 
lThe control group included 66 patients with colonoscopy-verified healthy controls 
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Circulating hypermethylated DNA fragments have also yielded prognostic infor-
mation. Some of the hypermethylation biomarkers are associated with advanced stage 
CRC (e.g. ALX4, FBN2, and VIM).171–173 These individual hypermethylation bi-
omarkers could therefore indicate the presence of micro or macro metastasis with 
poor prognosis. However, circulating hypermethylated DNA fragments are not solely 
surrogate markers for cancer stage. Wallner et al. (2006) showed that the presence of 
HLTF and/or TMEFF1 hypermethylation inferred increased mortality (HR = 3.4, 
95%CI[1.4; 8.1]), when adjusted for stage at the time of diagnosis. Further analysis 
of HLTF and TMEFF1 by Philipp et al. (2012) showed that the biomarkers mainly 
provided prognostic information in stage IV CRC.174 This shows that circulating hy-
permethylated DNA provides individual prognostic information, suggesting that they 
may be biomarkers for aggressive CRC.   
Table 5 Stool-based hypermethylation biomarkers in colorectal cancer 
Gene Sensitivity, % (n) Specificity, % (n) Method 
BMP3 100% (9/9) 91.4% (32/35)a QuARTS 
HIC1 42.3% (11/26) 98.0% (49/50)b MSP 
miR-34a 76.6% (63/82) 95.0% (38/40) MSP 
miR-34b/c 93.6% (74/79) 100% (40/40) MSP 
OSMR 37.7% (26/69) 95.1% (77/81)c qMSP 
NDRG4 60.7% (17/28) 93.3% (42/45)d qMSP 
PHACTR3 65.9% (29/44) 100% (30/30) qMSP 
SPG20 80.2% (77/96) 100% (30/30)e MSP 
SEPT9 20.0% (7/35) 100% (26/26) PSQ 
SFRP1 84.2% (16/19) 85.7% (12/14) MSP 
SFRP2 76.9% (10/13) 76.9% (10/13) qMSP 
SFRP2 94.2% (49/52) 95.8% (23/24)f  MSP 
SFRP2 87.0% (60/69) 93.3% (28/30)g qMSP 
SFRP2 84.0% (142/169) 54.0% (34/63)h MSP 
TFPI2 75.8% (50/66) 93.3% (28/30)i qMSP 
TFPI2 68.3% (41/60) 100% (30/30)j MSP 
VIM 45.7% (43/94) 90.0% (178/198) MSP 
VIM 72.5% (29/40) 86.9% (106/122)k MSP 
VIM 38.3% (23/60) 100% (37/37)l MSP 
VIM 40.9% (9/22) 94.7% (36/38) Methyl-beaming 
VIM 54.5% (18/35) 86.4% (19/22) PSQ 
Note. References for the individual studies are provided in the appended article. Unless otherwise specified, the control group was only 
specified as healthy. MSP = Methylation-specific PCR; qMSP = Quantitative methylation-specific PCR; PSQ = Pyrosequencing; 
QuARTS = Quantitative allele-specific real-time target and signal amplification 
aThe control group included 35 controls with inflammatory bowel disease but without colorectal neoplasia. 
bThe control group included 32 controls with normal colonoscopies, 9 patients with hyperplastic polyps, and 9 patients with inflammatory bowel disease. 
cThe control group included 81 colonoscopy-verified healthy controls. 
dThe control group included 45 colonoscopy-verified healthy controls. 
eThe control group included 30 colonoscopy-verified healthy controls. 
fThe control group included 24 age-matched colonoscopy-verified healthy controls. 
gThe control group included 30 colonoscopy-verified healthy controls. 
hThe control group included 63 controls only specified as benign cases. 
iThe control group included 30 colonoscopy-verified healthy controls. 
jThe control group included 30 colonoscopy-verified healthy controls. 
kThe control group included 122 colonoscopy-verified healthy controls. 





Studies analysing hypermethylated DNA from stool samples, have primarily fo-
cussed on candidate gene approaches. The presence of BMP3, PHACTR3, SFRP2, 
SPG20, TFPI2, TMEFF2, and VIM indicated early stage CRC or precancerous le-
sions.175–180 Hypermethylated VIM was even commercialised (ColoSure®; Laboratory 
Corporation of America, Burlington, North Carolina, USA) , however it is not rec-
ommended for use by any agency and has largely been replaced by the FDA approved 
Cologuard® test (Exact Sciences Corporation, Madison, Wisconsin, USA). Co-
loguard® is a combined assay for aberrantly methylated BMP3 and NDRG4 promoter 
regions, KRAS mutation, β-actin, as well as an immunochemical assay for human 
haemoglobin. A large scale cross sectional study showed improved sensitivity for 
advanced precancerous lesions (42.4%) compared with iFOBT alone (23.8%).152 
However, the specificity of iFOBT was superior to the specificity achieved by the 
combined assay (96.4% and 89.8% respectively) leading to a false positive rate of the 
iFOBT of 3.6% and a false positive rate of the multitarget DNA test of 10.2%. The 
discovery of improved biomarkers for CRC detection could replace the markers cur-
rently implemented in the Cologuard® test.  
Although the literature surrounding hypermethylated DNA fragments as biomarkers 
for CRC detection is growing rapidly, and SEPT9 has been commercialised as a blood 
based CRC screening biomarker, there is some ambiguity in the current diagnostic 
accuracy studies. Presently, most of the studies conducted show a remarkable de-
crease in test performance from the initial development studies to the subsequent val-
idation studies (e.g. SEPT9). This decrease is somewhat to be expected, however, it 
indicates that only utilising individual moleculat biomarkers, could lead to decreased 
test performance in CRC screening. The multitarget stool test (Cologuard®) and the 
results on the combination of ALX4, SEPT9, and TMEFF2 as a blood based test, 
shows that biomarker panels of hypermethylated DNA fragments are more promising 
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4.2. PATIENT POPULATION 
The study population consisted of consecutive CRC patients referred for surgery. The 
210 patients, from whom blood samples were available, were reviewed, leading to 
the exclusion of twelve patients: seven with benign disease or non-CRC, three with-
out residual cancer after endoscopic resection, one patient who initially refused sur-
gery, and one patient from whom informed consent could not be retrieved. Five ad-
ditional patients were also excluded, because the reference gene (MEST) could not 
be amplified during PCR analysis (Supplementary figure 2).  
Table 6 Patient characteristics 
 Colorectal cancers Healthy controls 
N 193 102 
Age, mean (SD) 67.5 (11.5) 64.7 (14.2) 
Sex, n (%)     
Male 119 (61.7) 55 (53.9) 
Female 74 (38.3) 47 (46.1) 
Smoke status, n (%)     
Never smoker 68 (35.7) 31 (30.4) 
Current smoker 77 (39.9) 28 (27.5) 
Previous smoker 43 (22.3) 24 (23.5) 
Unknown 5 (2.6) 19 (18.6) 
CEA-levels     
≤ 5 ng/ml 141 (73.1) 91 (89.2) 
> 5 ng/ml 52 (26.9) 11 (10.8) 
Tumour, n (%)     
T1 3 (1.6) - - 
T2 30 (15.5) - - 
T3 120 (62.2) - - 
T4 34 (17.6) - - 
T-unknown 6 (3.1) - - 
Node, n (%)     
N0 121 (62.7) - - 
N1 38 (19.7) - - 
N2 28 (14.5) - - 
N-unknown 6 (3.1) - - 
Metastasis, n (%)     
M0 159 (82.4) - - 
M1 34 (17.6) - - 
Note. The number (N) of patients in each patient group along with the mean age and standard deviations 
(SD) in each group. The number (n) and percentages (%) of patients according to sex, smoke status and 
carcinoembryonic antigen levels along with the colorectal cancer patients according to the tumour, node, and 
metastasis (TNM) classification system is also presented. 
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This left 193 CRC patients and 102 colonoscopy verified healthy controls. The re-
maining control group included 33 patients with resectable adenomas (all  < 1 cm in 
size and without high grade dysplasia) (Table 6).  All patients were used in the eval-
uation of hypermethylated DNA fragments as detection biomarkers for CRC. Only 
CRC patient samples were used in the evaluation of the prognostic properties of cell-
free DNA hypermethylation. 
 
4.3. COLORECTAL CANCER DETECTION 
The 30 gene promoter regions chosen from the literature study were utilised as po-
tential predictor variables for CRC detection. These hypermethylated promoter re-
gions were evaluated in blood samples from the patients described above. The DNA 
concentrations in the plasma samples from the two patient populations were highly 
similar, with a median (range) of 4.10 ng/ml (0.31-52.19) in the control group and 
4.00 ng/ml (0.26-132.58) in the CRC group (p = 0.982). The median number of hy-
permethylated DNA promoter regions (range) were four (1-11) and five (0-28) in the 
CRC group (p = 0.212). The correlation between DNA concentrations and the num-
ber of hypermethylated promoter regions is presented in Supplementary figure 3. 
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On an individual level, each of the hypermethylated DNA fragments had limited abil-
ity to distinguish CRC patients from healthy controls (Table 7). The marker showing 
most promise was ALX4 with a sensitivity of 28.5% at 99.0% specificity. Other mark-
ers (e.g. APC, NPTX2, and TAC1) were more sensitive, but with lacking specificity. 
Table 7 Promoter hypermethylation according to patient group 
 Colorectal cancer(N=193)  Healthy controls (N=102) 
 N % 95% CI  N % 95% CI 
ALX4 55 28.5 22.2 35.4  1 1.0 0.0 5.3 
APC 81 42.0 34.9 49.3  33 32.4 23.4 42.3 
BMP3 55 28.5 22.2 35.4  11 10.8 5.5 18.5 
BNC1 23 11.9 7.7 17.3  13 12.7 7.0 20.8 
BRCA1 49 25.4 19.4 32.1  22 21.6 14.0 30.8 
CDKN2A 18 9.3 5.6 14.3  4 3.9 1.1 9.7 
HIC1 11 5.7 2.9 10.0  1 1.0 0.0 5.3 
HLTF 22 11.4 7.3 16.7  4 3.9 1.1 9.7 
MGMT 11 5.7 2.9 10.0  1 1.0 0.0 5.3 
MLH1 87 45.1 37.9 52.4  44 43.1 33.4 53.3 
NDRG4 18 9.3 5.6 14.3  0 0.0 0.0 3.6 
NPTX2 135 69.9 62.9 76.3  60 58.8 48.6 68.5 
NEUROG1 40 20.7 15.2 27.1  20 19.6 12.4 28.6 
OSMR 22 11.4 7.3 16.7  7 6.9 2.8 13.6 
PHACTR3 28 14.5 9.9 20.3  6 5.9 2.2 12.4 
PPENK 20 10.4 6.4 15.6  4 3.9 1.1 9.7 
RARB 49 25.4 19.4 32.1  71 69.6 59.7 78.3 
RASSF1A 22 11.4 7.3 16.7  16 15.7 9.2 24.2 
SDC2 47 24.4 18.5 31.0  6 5.9 2.2 12.4 
SEPT9 47 24.4 18.5 31.0  5 4.9 1.6 11.1 
SFRP1 42 21.8 16.2 28.3  7 6.9 2.8 13.6 
SFRP2 39 20.2 14.8 26.6  18 17.6 10.8 26.4 
SPG20 30 15.5 10.7 21.4  12 11.8 6.2 19.6 
SST 58 30.1 23.7 37.1  32 31.4 22.5 41.3 
TAC1 102 52.8 45.6 60.1  48 47.1 37.1 57.2 
THBD 19 9.8 6.0 14.9  1 1.0 0.0 5.3 
TFPI2 14 7.3 4.0 11.9  2 2.0 0.2 6.9 
VIM 34 17.6 12.5 23.7  12 11.8 6.2 19.6 
WIF1 19 9.8 6.0 14.9  4 3.9 1.1 9.7 
WNT5A 12 6.2 3.3 10.6  5 4.9 1.6 11.1 
Note. The number (N) of patients in each patient group along with the percentages (%) of patients according to each hypermethylated 
with corresponding 95% confidence intervals (95% CI) 
 
The initial univariate screening left 19 of the potential predictor variables along with 
sex and age for the subsequent stepwise logistic regression. Through the stepwise 
selection process (Figure 15a) we considered Model 12 to be the most applicable due 
to a reduced model complexity, and because the model did not differ from the model 
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produced by penalised regression. Incorporation of CEA as a binary variable (> 5 
ng/ml) did not lead to a difference in model selection, and CEA was therefore not 
incorporated in the model. The potential predictor variables were all evaluated for 
potential interactions, revealing an interaction between RARB and VIM (p < 0.001). 
However, the inclusion of this interaction term in the final model did not provide 
additional information.  All models passed the Hosmer-Lemeshow test at the 0.05 
significance level. 
 
Figure 15 Stepwise selection process and model performance  
A) Logistic regression with stepwise backwards selection. Potential predictor variables in the top row and model num-
ber in the left column. Area under the receiver operating characteristics (ROC) curve (AUC) are situated to the right. B) 
ROC curve for all stage CRC with a non-optimism corrected AUC of 0.8870. C) ROC curve for stage I and II CRC 
with a non-optimism corrected AUC of 0.8775. 
 
Model 12 included seven hypermethylated promoter regions (ALX4, BMP3, NPTX2, 
RARB, SDC2, SEPT9, and VIM) along with sex and age. The model had the ability 
to distinguish CRC patients from colonoscopy verified healthy controls with an opti-
mism corrected AUC of 0.860 (optimism = 0.027).   Removal of 33 patients with 
adenomas from the control group did not alter the immediate efficacy of the predic-
tion model (optimism corrected AUC = 0.863). Importantly, the model also had the 
ability to detect early stage CRC (stage I and II) with an optimism corrected AUC of 
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0.853 (optimism = 0.025). The model building process was done considering hyper-
methylation on a qualitative scale only. We therefore considered the Ct value of each 
individual DNA promoter region in order to assess the amount of information lost 
due to dichotomisation (Supplementary table 4). Inspection of the data suggests that 
there could be some difference in Ct value between CRC patients and healthy con-
trols, suggesting that there was more of the individual markers present in the samples 
from the CRC patients. The effect of this difference in Ct value could, however, not 
be assessed in the current framework due to limited power. 
 
4.4. COLORECTAL CANCER PROGNOSIS 
In this part, we evaluated the same 30 cell-free hypermethylated DNA promoter re-
gions as biomarkers for CRC stage and prognosis. This was in order to assess the 
added information provided by circulating hypermethylated DNA fragments to the 
current TNM staging system.  
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The median cell-free DNA levels were similar between stages (3.73 ng/ml for stage 
I and 4.27 ng/ml for stage IV CRC) (p = 0.128).  
The median number (range) of hypermethylated promoter regions in the CRC pa-
tients with distant metastasis was nine (0-28) compared to all other CRC patients with 
a median number of five (0-19) (p < 0.0001). However, the number of cell-free hy-
permethylated promoter regions were not associated with T- and N-classification. 
Table 8 Promoter hypermethylation according to CRC stage 
 AJCC stage 7th edition 
 I II III IV 
 N % N % N % N % 
ALX4 5 2.6 19 9.8 13 6.7 18 9.3 
APC 12 6.2 38 19.7 14 7.3 17 8.8 
BMP3 5 2.6 27 14.0 7 3.6 16 8.3 
BNC1 0 0.0 6 3.1 2 1.0 15 7.8 
BRCA1 9 4.7 23 11.9 9 4.7 8 4.1 
CDKN2A 4 2.1 6 3.1 1 0.5 7 3.6 
HIC1 0 0.0 2 1.0 1 0.5 8 4.1 
HLTF 1 0.5 6 3.1 6 3.1 9 4.7 
MGMT 1 0.5 4 2.1 1 0.5 5 2.6 
MLH1 12 6.2 42 21.8 18 9.3 15 7.8 
NDRG4 1 0.5 5 2.6 4 2.1 8 4.1 
NPTX2 18 9.3 56 29.0 34 17.6 27 14.0 
NEUROG1 5 2.6 18 9.3 6 3.1 11 5.7 
OSMR 1 0.5 7 3.6 2 1.0 12 6.2 
PHACTR3 2 1.0 10 5.2 5 2.6 11 5.7 
PPENK 3 1.6 4 2.1 3 1.6 10 5.2 
RARB 3 1.6 20 10.4 11 5.7 15 7.8 
RASSF1A 3 1.6 8 4.1 4 2.1 7 3.6 
SDC2 4 2.1 15 7.8 9 4.7 19 9.8 
SEPT9 3 1.6 18 9.3 7 3.6 19 9.8 
SFRP1 3 1.6 9 4.7 9 4.7 21 10.9 
SFRP2 3 1.6 8 4.1 10 5.2 18 9.3 
SPG20 2 1.0 10 5.2 6 3.1 12 6.2 
SST 7 3.6 21 10.9 11 5.7 19 9.8 
TAC1 16 8.3 39 20.2 25 13.0 22 11.4 
THBD 0 0.0 4 2.1 3 1.6 12 6.2 
TFPI2 1 0.5 3 1.6 1 0.5 9 4.7 
VIM 5 2.6 11 5.7 6 3.1 12 6.2 
WIF1 2 1.0 3 1.6 2 1.0 12 6.2 
WNT5A 0 0.0 4 2.1 2 1.0 6 3.1 
Note. The number (N) and percentages (%) of colorectal cancer (CRC) patients (N=193) with positive amplification of hypermethylated 
promoter regions in plasma samples according to the American Joint Committee on Cancer (AJCC) staging system 7th Edition. 
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There was a marked increase in the frequency of promoter hypermethylation at all 
regions from stage I to stage II. However, for some of the promoter regions (e.g. APC, 
MLH1, NPTX2, and TAC1) there was an apparent decrease in methylation frequency 
from stage II to stage IV (Table 7). This indicates a large difference in methylation 
patterns between CRCs with metastasis, and tumour invasion. 
There was an overall five-year survival of 62.2% (120/193) among the CRC patients. 
Patient survival was closely associated with the number of hypermethylated DNA 
fragments (Figure 17). The presence of more than four hypermethylated promoter 
regions was significantly associated with decreased overall survival (p < 0.01). The 
difference between having five to ten hypermethylated promoter regions in plasma 
and more than ten were only marginally different (p = 0.09). 
 
Figure 17 Survival according to hypermethylated DNA  
The light blue line represents patients with 0-4, the dark blue line presents patients with 5-10, and the red line patients 
with more than 10 hypermethylated promoter regions measured in plasma. The number of patients at risk in each groups 
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Table 9 Hazard models 
 Univariable Cox-regression  Multivariable Cox-regression 
 HR 95% CI P-value  HR 95% CI P-value 
Sex 1.11 0.72 1.71 0.642  0.99 0.61 1.60 0.968 
Age 1.00 1.00 1.00 0.005  1.00 1.00 1.00 <0.001 
CEA 2.42 1.57 3.71 <0.001  1.50 0.89 2.52 0.126 
Stage I 1.00     1.00    
Stage II 3.77 1.15 12.34 0.028  3.75 1.13 12.47 0.031 
Stage III 4.99 1.48 16.88 0.010  5.09 1.45 17.78 0.011 
Stage IV 22.36 6.76 73.92 <0.001  25.07 6.77 92.87 <0.001 
ALX4 2.18 1.41 3.38 <0.001  1.50 0.86 2.63 0.157 
BNC1 2.93 1.69 5.07 <0.001  1.44 0.64 3.26 0.377 
HIC1 3.04 1.46 6.32 0.003  0.79 0.29 2.14 0.649 
RARB 2.06 1.31 3.23 0.002  1.99 1.07 3.72 0.031 
RASSF1A 2.75 1.57 4.81 <0.001  3.35 1.76 6.38 <0.001 
SDC2 1.94 1.23 3.07 0.005  0.71 0.34 1.49 0.368 
SEPT9 1.91 1.21 3.02 0.006  0.71 0.37 1.37 0.313 
SFRP1 1.91 1.21 3.02 0.006  0.71 0.37 1.37 0.313 
SFRP2 2.42 1.53 3.84 <0.001  0.98 0.46 2.06 0.955 
SPG20 2.66 1.67 4.24 <0.001  1.73 0.85 3.51 0.131 
TFPI2 2.67 1.38 5.19 0.004  0.92 0.33 2.52 0.863 
THBD 2.95 1.68 5.18 <0.001  0.69 0.29 1.64 0.405 
WIF1 3.26 1.83 5.83 <0.001  0.78 0.31 1.95 0.592 
APC 1.19 0.77 1.82 0.440      
BMP3 1.45 0.92 2.29 0.106      
BRCA1 0.98 0.60 1.61 0.950      
CDKN2A 1.42 0.71 2.84 0.317      
HLTF 1.87 1.04 3.38 0.038      
MGMT 2.27 1.04 4.93 0.039      
MLH1 1.43 0.93 2.20 0.100      
NDRG4 1.54 0.80 2.99 0.197      
NPTX2 1.25 0.77 2.02 0.365      
NEUROG1 1.05 0.62 1.79 0.857      
OSMR 1.52 0.83 2.81 0.178      
PHACTR3 1.54 0.88 2.70 0.128      
PPENK 1.94 1.07 3.50 0.029      
SST 1.40 0.89 2.21 0.146      
TAC1 1.56 1.01 2.42 0.047      
VIM 1.82 1.10 3.00 0.020      
WNT5A 1.82 0.84 3.96 0.129      
Note: The univariable analysis of overall mortality using univariable Cox regression analysis. Variables reaching a significance level (p-
values < 0.01) were analysed in the subsequent multivariable Cox regression analysis, adjusting for sex, age, CEA-levels and American 
Joint Committee on Cancer (AJCC) staging system. Individual hazard ratios (HR) with corresponding 95% confidence intervals (95% 
CI) and P-values. Carcinoembryonic antigen (CEA) was considered positive if the levels were above 5 mg/l for non-smokers, and if the 
levels were above 10 mg/l for smokers. 
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The majority of the hypermethylated DNA promoter regions inferred a poor progno-
sis. Thus, in order to limit the number of variables included in the multivariable Cox 
regression analysis we only included markers with a p-value below 0.01 (Table 8).  
After adjustment for each of the biomarkers, stage was still the clearest predictor for 
adverse outcome. However, RARB and RASSF1A remained significantly associated 
with decreased overall survival, after adjusting for sex, age, pre-treatment CEA levels 
and stage. This decrease in overall survival remained, even after stratification for 
tumour localisation (colon versus rectum). In order to visualise the effect of RARB 
and RASSF1A on the survival of CRC patients, we computed the Kaplan Meier esti-
mates for the positivity of the two markers (Figure 18). 
 
Figure 18 Survival according to RARB and RASSF1A hypermethylation  
The dark blue line represents patients without hypermethylation of either promoter region and the red line represents 
patients with hypermethylated RARB and/or RASSF1A. The hazard ratio (HR) was computed using Cox regression with 
95% confidence interval reported in brackets. The Log-rank test for equality of survivor functions was used to compute 
the p-value. The number of patients at risk in each groups is presented below the graph.  
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Of the 193 CRC patients, 144 received curatively intended surgical resections. Of 
these patients, 29 patients developed a local or metastatic recurrence. In order to as-
sess if the number of circulating hypermethylated DNA promoter regions were asso-
ciated with a risk of CRC recurrence, a cumulative incidence plot was computed for 
patients with 0-4 hypermethylated DNA promoter regions and patients with more 
than five (Figure 19). 
 
Figure 19 Risk of recurrence according to hypermethylated DNA  
Cumulative incidence of recurrence when adjusting for death as a competing outcome (Aalen-Johansen estimator). The 
dark blue line represents patients with 0-4, and the red line represents patients with more than five hypermethylated 
promoter regions measured in plasma. 
 
The risk of recurrence at three years after diagnosis was 12.8% in the group with a 
low number of circulating hypermethylated DNA promoter regions compared to 
23.8% in the group with a high number. The nearly two-fold increased risk ratio at 
three years (RR = 1.86, 95%CI [0.88; 3.92]) was, however, not statistically signifi-
cant (P = 0.101). Adjustment for stage did not alter the immediate conclusion (RR = 
1.91, 95%CI [0.91; 4.04]). It was not possible to determine, if any of the individual 



























    
CHAPTER 5. DISCUSSION 
Throughout the current thesis, a select few hypermethylated DNA promoter regions 
have been evaluated for their utility as blood based biomarkers for CRC detection 
and their association with the outcome of CRC patients. It appears, that circulating 
hypermethylated DNA measured in plasma (ALX4, BMP3, NPTX2, RARB, SDC2, 
SEPT9, and VIM) may be utilised as blood based biomarkers for CRC detection and 
some of them yield prognostic information (RARB and RASSF1A). Moreover, a high 
number of circulating hypermethylated DNA promoter regions seems to be related to 
decreased survival and a higher risk of disease recurrence.  
 
5.1.  LIMITATIONS 
These results are indeed promising, however, before a blood based test can be utilised 
in the clinic, subsequent external validation must be conducted. Methodological lim-
itations could lead to spurious associations, and these limitations will be elaborated 
below.  
The first limitation encompasses the origin of the cell-free hypermethylated DNA 
fragments. The majority of circulating cell-free DNA originates from the turnover of 
normal cells.181 We analysed our blood samples for the presence of putative bi-
omarkers found through our initial literature study. We analysed these biomarkers in 
plasma samples only, and did not attempt to ensure their presence in paired patient 
tumours. This is an important caveat, because it makes us unable to ensure that the 
circulating hypermethylated DNA promoter regions are entirely tumour specific. In 
order to ensure the detection of tumour derived circulating DNA, we utilised the fact, 
that DNA from tumour cells is highly fragmented (mainly smaller than 150 bp) and 
designed our primers and probes accordingly (the largest amplified region was 152 
bp (WNT5A)).182 This does not ensure cancer specificity. However, regardless of 
origin, the performance of our biomarker panel for CRC remains promising (opti-
mism corrected AUC = 0.860). 
The second limitation is sample volume. The current thesis relies on the analysis of 
blood samples collected from a previous study.147 One plasma sample was available 
for analysis for each patient, and in some instances, the sample volume was very low 
(350-1,000 μl plasma). As previously stated, the copy number of circulating tumour 
derived DNA is below 10 copies per 5,000 μl plasma.123 Fortunately, the ability to 
detect our methylated reference gene (MEST1) was not affected by low plasma vol-
umes (Supplementary figure 2), however, the limited amount of starting volume 
could lead to a decreased amount of cell-free tumour specific DNA for analysis. In 
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contrast, the next generation SEPT9 test (Epi proColon® 2.0 [Epigenomics AG Cor-
poration, Berlin, Germany]) requires a minimum of 3,500 μl plasma for DNA extrac-
tion.162 Whether the low performance of SEPT9 (sensitivity = 24.4%) reported in our 
study was merely a result of the limited amount of plasma remains unknown. Future 
evaluation of the developed biomarker panel should address this issue by isolating 
DNA from a larger volume of starting material. 
The third limitation relates to the utilisation of stored blood samples. Prolonged stor-
age of DNA may lead to substantial loss, with annual degradation rates of approxi-
mately 7-30%.183,184 Another problem could be attributed to cell lysis due to pro-
longed processing time before storage, leading to a higher DNA yield originating 
from the intracellular space. This is an issue regardless of sample material (plasma/se-
rum), but only markedly influencing the analysis of serum samples.185 However, a 
recent study found that the degree of DNA methylation was not affected by prolonged 
processing (up to 72 hours) as long as samples were kept at room temperature.186 In 
our study, we used EDTA plasma samples, and the processing never exceeded two 
hours. This suggests that the effect of processing issues should be limited. However, 
these considerations should be remembered in the future validation of the proposed 
biomarkers for CRC detection and to ensure that RARB and RASSF1A are indeed 
valid predictors for poor overall survival, regardless of stage in CRC patients.  
The fourth limitation concerns the analytical method for hypermethylation detec-
tion.141 Our method only allows detection of methylation at one site in the genome. 
Any discordance in primer/probe selection between the studies included in our re-
view, and our current experiment could therefore lead to differences in marker per-
formance. Moreover, we conducted our two-step PCR using methylation primers and 
probes in order to ensure the specificity of the assay. This could lead to false negative 
results, and a decrease in individual biomarker performance. However, we conducted 
this type of nested PCR in order to ensure the sensitivity of the assay for the limited 
amounts of hypermethylated DNA fragments detectable in plasma. 
The fifth limitation revolves around the bisulphite conversion protocol. In our study 
we apply a rapid bisulphite protocol which should ensure complete conversion at an 
optimal DNA yield. This protocol was recently assessed to be suboptimal.187 We have 
therefore compared kit with the second highest yield after bisulphite conversion (EZ 
DNA Methylation-DirectTM; Zymo Research, Irvine, California, USA) and found that 
our test was more than comparable (Madsen P.H. [unpublished data]). The discrep-
ancy between our results, and those presented by Ørntoft et al. (2017) may be due to 
subtle laboratory differences leading to decreased performance.187 Future validation 
studies could employ more than one method to ensure optimal conversion and yield. 
The sixth limitation surrounds multiple comparisons. In order to select biomarkers 
for CRC detection, we relied on a logistical selection process with backwards elimi-




lead to false positive associations. In the model development process, this phenome-
non is coined overfitting. In order to estimate how much overfitting was present, we 
conducted Leave-pair-out cross validation.188 This is in line with the current guide-
lines for studies surrounding predictive modelling.189 However, the issue of false pos-
itive and false negative findings remains (with similar effects in the study on CRC 
prognosis), and external validation must be conducted, before any of the biomarkers 
can be utilised in the clinical setting. 
The seventh and final limitation has previously been mentioned, and regards the lack 
of external validation. This is critical in order to properly assess the utility of the 
developed biomarker panel. However, inclusion of a validation cohort along with the 
analysis of plasma samples, was not possible in the predefined study period. 
 
5.2. STRENGTHS 
The main strength of the current study resides in the usage of a well-defined CRC 
cohort along with a select control population of colonoscopy verified healthy controls 
of a similar age and gender distribution. These CRC patients were included consec-
utively, and followed for up to five-years after diagnosis. We developed our bi-
omarker panel using a rather large cohort compared to the studies already in the lit-
erature. Moreover, previous studies have often used less than optimal control groups 
for biomarker development, and validation of individual circulating hypermethyla-
tion biomarkers are generally lacking (one exception being SEPT9).190  
Another strength is the use of multiple markers for CRC detection. Our study sup-
ports the results made by other groups, that a panel of hypermethylated biomarkers 
reaches a greater detection rate compared with individual biomarkers.156,170 Even 
though the SEPT9 test (Epi proColon®) has reached FDA approval as an alternative 
CRC screening test, it relies on the sole detection of SEPT9 methylation in plasma. 
The implementation of multiple markers in CRC screening tests would lead to in-
creased detection rates, as shown in the Cologuard® study.152  
The current study relies on CRC detection using plasma based biomarkers. If these 
biomarkers are used in CRC screening, it could potentially increase adherence rates. 
In a study funded by Epigenomics AG, most patients non-adherent to an initial 
screening colonoscopy stated that they would prefer the SEPT9 blood test (83%) over 
iFOBT (15%), with the remaining (2%) refusing any type of screening.191 Whether 
an apparent preference for a blood based screening test will translate into improved 
adherence to the CRC screening programme in Denmark remains to be elucidated. 
Lastly, our study is in full accordance with the current guidelines on predictive mod-
elling.189 
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5.3. COMPARISON TO THE CURRENT LITERATURE 
The results provided by the current study are generally comparable to the results 
found in the literature. Albeit the results are more modest. 
Previous studies have found that the amount of circulating cell-free DNA is increased 
in cancer patients, with levels being increased approximately four times in CRC pa-
tients compared to healthy controls.120,192 This is in contrast with the results from our 
analysis, where concentrations of cell-free DNA were similar (~4 ng/ml). However, 
it should be emphasised, that most studies on DNA concentrations in cancer patients 
have used blood donors as controls, which are not necessarily comparable to the oth-
erwise healthy individuals present in a screening population.193 Moreover, a signifi-
cant increase in cell-free DNA is primarily found in serum samples, whereas we used 
plasma samples in our analysis. Whether the annual degradation rates of cell-free 
DNA has affected the CRC samples more compared to the controls is unknown, but 
seems highly speculative. An increase in DNA concentrations have more reliably 
been shown in lung and pancreatic cancer, with DNA concentrations being approxi-
mately four to five fold higher in patients compared to controls.194,195 However, gen-
erally the overlap is rather large with reports of average concentrations of up to 44 
ng/ml measured in plasma samples from healthy individuals.196 This is in line with 
the findings in our study with ranges from 0.31 to 52.19 ng/ml for healthy controls 
and from 0.26 to 132.58 ng/ml for CRC patients. This shows some evidence against 
the utilisation of cell-free DNA levels as an immediate cancer detection biomarker - 
at least in the case of CRC. 
 
5.3.1. DETECTION BIOMARKERS 
The performance of each individual molecular marker for CRC in our biomarker 
panel is more modest than that of previous studies. None of the hypermethylated pro-
moter regions analysed in our study could be used as individual biomarkers for CRC 
detection. With the exception of SEPT9, this is in line with results reported in the 
bulk of the present literature. The three most recent studies on SEPT9 report sensi-
tivities of 83.0-87.1% and specificities of 82.1-95.9%.197–199 These results are indeed 
promising, however, the SEPT9 assay has also been shown to be affected by age, 
stage of disease and benign disorders.168 Moreover, the results from the PRESEPT 
study shows the real life screening scenario, and herein the assay sensitivity was only 
48.2% for CRC and precancerous lesions.151 As such, SEPT9 cannot be recom-
mended as an individual biomarker for CRC screening. However, as our results sug-
gest, it may be utilised as part of a biomarker panel.  
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Another example of the limited use of individual CRC biomarkers is NEUROG1. 
NEUROG1 methylations was identified and proved to be more specific than ALX4 
methylation with a sensitivity of 55.5% at 81.3% specificity.158 In contrast, our anal-
ysis showed that not only was ALX4 the superior of the two markers, NEUROG1 was 
also equally methylated in CRC patients and healthy controls (~20%). This further 
suggests the use of multigene panels for CRC detection and promotes ALX4 as a 
promising marker for CRC detection. 
Previous reports on multigene panels for CRC detection have yielded promising re-
sults with APC, MGMT, RASSF2A, and WIF1 providing a sensitivity of 86.5% at 
92.1% specificity.156 We evaluated three of these markers, and found that their indi-
vidual performances were limited (sensitivities = 5.7-42.0% with specificities = 67.6-
99.0%). The second largest study on combined hypermethylation biomarker panels 
for CRC detection evaluated ALX4, SEPT9, and TMEFF2.170 The combination pro-
duced results comparable with our study (sensitivity of 80.7% at 90.0% specificity). 
Two of these markers were also implemented in our biomarker panel, however, the 
individual sensitivities were only 28.5% and 24.4%, respectively compared to 47.8% 
and 74.7% in the previous study.170 This shows some of the difficulties in reproducing 
the results from putative biomarker studies. Some of this discrepancy could arise due 
to factors listed in the limitations section.   
We evaluated BMP3 and NDRG4 due to the interesting findings in stool samples.152 
BMP3 was implemented in the model, and while NDRG4 was solely positive in CRC 
patients, it was only detected in 9.3% of CRC plasma samples. NDRG4 therefore 
seems highly specific for CRC, without the necessary sensitivity required for an in-
dividual blood based CRC biomarker. This conclusion is supported by a recent report 
on NDRG4 hypermethylation in 27% of plasma samples compared with 53% of stool 
samples in CRC patients.200 The vast majority of colorectal tumours (like other cancer 
types) contain numerous cellular clones with only a subset of shared genetic or epi-
genetic alterations.201 Differences in marker performance may be a result of this in-
tratumour heterogeneity. A difference in gene expression at the invasive front com-
pared with the central tumour area and the luminal part, has been proposed for β-
catenin.202 The molecular characteristics may therefore be different with regard to the 
invasion front (located near the invading blood vessels) and the luminal front. An-
other factor could be differences in the constitution of circulating DNA versus stool 
DNA. This makes the choice of media for molecular marker extraction critical. Fu-
ture studies on biomarkers for CRC detection should keep this heterogeneity in mind 
when testing putative biomarker panels in stool or blood samples. 
With the exception of RARB, all of the hypermethylated biomarkers implemented in 
the model for CRC detection were more frequent in the plasma of CRC patients com-
pared to controls. RARB was found in 69.6% of healthy controls compared to 25.4% 
of CRC patients. Conversely, RARB methylation has been found in serum samples of 
95.9% breast cancer patients compared to 0.0% in healthy women.203 Moreover, 
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RARB has also been detected in rectal tumours with lymph node metastases.204 In 
contrast, RARB was only hypermethylated in 1.6% of stage I CRC followed by a 
sharp increase to 20.7% for stage II and 7.8% for stage IV disease. This makes the 
utilisation of RARB as a biomarker for CRC enigmatic. On one hand, RARB hyper-
methylation is a biomarker for advanced tumours with some association to distant 
metastasis. On the other hand, RARB was more frequently hypermethylated in healthy 
controls above 66 years of age, and RARB methylation could likely just be a result of 
age related hypermethylation.205 Whether our results concerning RARB are coinci-
dental, requires further evaluation. 
In the future, improvements and refinements in the area of EWAS on circulating cell-
free DNA, as well as improvements in whole-genome bisulphite sequencing with 
minute amounts of starting material may lead to the detection of new biomarkers and 
possibly alter the performance of already existing CRC biomarkers.206 
 
5.3.2. PROGNOSTIC BIOMARKERS 
The data from our survival analysis quite clearly states, that increased CRC mortality 
is associated with an increase in circulating hypermethylated promoter regions.  
Previous studies have shown that increased cell-free DNA levels were associated 
with decreased overall and recurrence free survival in CRC patients.207 In our study, 
the levels of cell-free DNA did not differ between stage-groups, and were as such, 
not a good predictor for stage. We hypothesised, that the number of cell-free hyper-
methylated DNA promoter regions would be better suited as outcome predictors in 
CRC, and found it to be associated with metastatic disease. This is in line with pre-
vious results.171–173 Moreover, a large number of hypermethylated DNA promoter re-
gions were also a predictor for poor overall survival (possibly through the relation 
with stage IV disease). Univariate analysis also revealed that the majority of the an-
alysed biomarkers were associated with poor overall survival in CRC patients. 
Through our multivariable analyses, we discovered that RARB and RASSF1A were 
associated with poor survival in CRC patients, regardless of stage at the time of di-
agnosis. The presence of RARB and/or RASSF1A was associated with a two to three 
fold increase in overall mortality. Furthermore, an increased number of circulating 
hypermethylated DNA promoter regions were also associated with an increased risk 
of recurrence. This is in line with the studies on HLTF and TMEFF2 with reports of 
a three to four fold increase in mortality for patients with either of the two markers, 
and a more than two-fold increase in the risk of recurrence among patients with cir-
culating HLTF.174,208 The following studies on HLTF and TMEFF2, however, showed 
that the impact on prognosis was limited to stage IV CRC patients.209,210 We also 
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analysed the presence of HLTF methylation in our study, and while it was individu-
ally associated with poor survival (HR = 1.87, 95%CI [1.04; 3.38]) it was more often 
hypermethylated in patients with distant metastasis, and did not render prognostic 
information after adjustment for stage. 
Recently, SST hypermethylation was shown to be a promising individual serum bi-
omarker for overall survival in CRC.211 We also evaluated circulating SST hyper-
methylation as a biomarker for CRC prognosis, and found no association. This dif-
ference could be attributed to some of the factors listed in the limitations section. The 
most important difference could be the use of plasma in the present work compared 
to the use of serum reported by others. The same group also evaluated TAC1 hyper-
methylation and found no association with patient survival, which is in line with our 
results. This shows that there can be a marked difference in individual biomarker 
utilisation across studies and the comparison of results can be challenging.  
In our experiment, we only assessed the methylation status of previously identified 
promoter regions in blood samples of CRC patients. However, since then, the number 
of tissue studies in CRC have increased rapidly. Recent tissue-studies have revealed 
new putative biomarkers, which provide prognostic information. SHISA3 is transcrip-
tionally repressed in colorectal tumours and adenomas, and SHISA3 methylation has 
been shown to be a strong predictor for poor overall survival.212 Other prognostic 
biomarkers identified through tissue studies may provide improved accuracy for the 
stratification of CRC patients according to prognosis. 
The prognostic information provided by circulating hypermethylation biomarkers 
could aid in the choice of treatment for CRC patients. The presence of these individ-
ual biomarkers could imply the need for more intensive follow-up, and evaluation for 
the advent of local or metastatic recurrence, even after immediate curative resection. 
Whether our results on RARB and RASSF1A hypermethylation are reproducible war-
rants further validation in an independent sample of CRC patients. 
 
5.4. FUTURE BIOMARKER RESEARCH 
The search for new and improved biomarkers for CRC detection is ongoing. Cur-
rently the development of multi-biomarker hypermethylation assays are being readily 
developed and tested. Among these are the two-gene hypermethylation test (BCAT1 
and IKZF1) and the nucleosome test Nu.QTM (Belgian Volition SPRL, Namur, Bel-
gium).213,214 The two-gene hypermethylation assay has recently been evaluated as an 
adjunct to the iFOBT screening programme increasing compliance rates in patients 
who were otherwise not interested in screening.215 A planned large-scale Danish 
study conducted at Hvidovre Hospital, will include approximately 8000 patients in 
the evaluation of the Nu.QTM test as a triage test after a positive iFOBT, selecting 
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patients for subsequent colonoscopy.216 This could possibly lead to a decrease in the 
number of screening colonoscopies by ~25% (unpublished data). Whether the opti-
mal utilisation of these blood based tests are as an up-front screening method (replac-
ing the iFOBT) or as an adjunct to the current screening methods, in order to reduce 
the increasing burden of colonoscopies, remains to be established. 
 
5.5. PERSPECTIVES 
From the studies above it seems evident that there is both diagnostic and prognostic 
information rooted in these hypermethylated biomarkers.  
For the validation of the current biomarker panel for CRC detection, we have in-
cluded 102 patients with mild and moderate ulcerative colitis (November 2015 – July 
2017) and 193 colonoscopy verified healthy controls from the screening population 
in Denmark (August 2016 – April 2017). We plan to compare the circulating DNA 
hypermethylation status of the genes identified through this thesis with approxi-
mately 100 CRC patients retrieved from the Danish Cancer Biobank. In order to raise 
the sensitivity of the assay, we plan to increase the amount of input plasma for DNA 
isolation by two-fold. Such a study will provide evidence for or against the efficacy 
of our proposed model for CRC detection. Moreover, this will prove, or disprove, the 
prognostic information gained from RARB and RASSF1A hypermethylation. 
The current model for CRC detection using seven hypermethylated promoter regions 
is currently only on par with the current screening strategy using the iFOBT. A blood 
based biomarker panel should at least improve CRC detection, before it can replace 
the current method. Future studies will need to compare plasma-based assays and 
stool tests, in order to ensure improved performance by these tests. Furthermore, a 
thorough pipeline for biomarker evaluation should be employed to avoid waste and 
to increase reproducibility and comparison between laboratories.217 Currently, the use 
of molecular biomarkers for CRC screening, have only provided increased sensitiv-
ity.152 This enables the detection of more cancers, however, at the cost of decreased 
specificity. All patients who deliver a positive screening test have to undergo a sub-
sequent colonoscopy for the final diagnosis, putting a large burden on local hospital 
departments. Before current screening methods (using iFOBT) eventually can be re-
placed by circulating or stool based hypermethylation biomarkers, any improvement 
in sensitivity must be accompanied by a specificity matching the specificity of the 
iFOBT.  
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CHAPTER 6. CONCLUSION 
Circulating hypermethylated DNA fragments for cancer detection and prognosis have 
been thoroughly investigated for decades. However, none of these blood-based bi-
omarkers are currently being recommended in the screening setting or as tools for 
CRC staging or prognostication. 
In this thesis, the current knowledge surrounding cell-free hypermethylated DNA in 
stool and blood has been summarised. Even though several promising results have 
been proposed, most studies lack the reproducibility and performance justifying their 
immediate implementation in daily clinical practice. 
We therefore set out to evaluate some of the putative biomarkers already evaluated 
in the literature, as markers for CRC detection. Individual hypermethylated promoter 
regions proved to be limited in their ability to detect CRC, however, a panel of seven 
gene promoter regions (ALX4, BMP3, NPTX2, RARB, SDC2, SEPT9, and VIM) along 
with sex and age were able to distinguish CRC patients from healthy controls with a 
promising performance (optimism corrected AUC of 0.853 for stage I and II CRC).  
We also found that the number of hypermethylated promoter regions was associated 
with poor overall survival, and increased risk of recurrence. Moreover, we identified 
RARB and RASSF1A as predictors for increased mortality among CRC patients. 
These hypermethylated promoter regions could be used to identify patients who 
would benefit from a more intensive follow-up programme, or possibly adjuvant ther-
apy. 
These findings are only preliminary in nature and the methods utilised for the detec-
tion of cell-free promoter regions are rapidly evolving. This stresses the need for val-
idation in external cohorts to ensure the exploratory results. Moreover, the utilisation 
of more input material for analysis could improve test sensitivity. 
The years to come will elucidate if cell-free hypermethylated DNA fragments could 
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Supplementary figure 1 Hypermethylation analysis of cell-free plasma derived DNA  





Supplementary figure 2 Association between cycle threshold and the reference gene 
A) Sample volume according to cycle threshold (Ct) value of unmethylated MEST1. B) Sample volume according to Ct 
value of methylated MEST1. Five patients did not have amplification of the reference gene (noCT). These patients were 
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Supplementary figure 3 Cell-free DNA and hypermethylated DNA  
The concentration of cell-free DNA according to the number of hypermethylated promoter regions measured in plasma 
at baseline. Healthy controls are marked in blue and colorectal cancer patients with red. The dashed line represents the 
correlation between the values. Kendall’s rank coefficient (τ) is provided as a measure of the association. 
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